CCR eCRF Instructions Manual 2011

Manual for the Completion of the NCI / CCR / C3D Case Report Forms

Prepared by: The Harris IT Services (October 2011)

<u>Disclaimer:</u> This manual was developed by Harris IT Services for the National Cancer Institute's Center for Cancer Research (CCR). The material contained in it is solely for assisting data entry into CCR's Cancer Central Clinical Database (C³D) electronic case report forms.

Introduction

At the end of 2003, the National Cancer Institute's Center for Cancer Research (CCR) developed and started using the Cancer Central Clinical Database (C³D) - a client-server computer system - to capture data for oncology clinical trials research trials conducted at the CCR.

This manual contains the instructions for the completion of the NCI's standard Case Report Forms used in C³D.

The eCRF instruction manual is preceded by a General Instructions section which describes topics applicable to all eCRFs. This is followed by instructions for each form which include how to complete each field, what the validation rules are for the CRF, and what fields will be derived by the database. The Appendices include conversion tables and useful Internet and Intranet references and standard lab panels.

Changes to Case Report Forms since Last Version of the Manual Previous Versions of the eCRFs Instructions Manual

Case Report Forms Instructions

General Instructions

*updated

Adverse Events +

Baseline Medical History

Baseline Symptoms

Cardiac

Chimerism *

Concomitant Measures and Medications

Course Assessment

Course Initiation

Consults (new)

ECG

Eligibility Checklist

Enrollment *

Extent of Disease *

Extent of Disease (Neuro Oncology Branch) (new)

Follow up

Infection Episode

Labs *

Medical Record Numbers

Off Study *

Off Treatment

Pathology Report (new)

Pharmacokinetics

Physical Exams - Screening

Physical Exams - Courses

Prior Radiation Supplement

Prior Surgery Supplement

Prior Therapy Supplement

Prior Treatment Summary

Procedures

Radiation

Study Medication Administration

Storage (new)

Surgery

Survival

Transfusions

Urinary Excretions

Vital Signs

Appendices

Appendix I - Conversion Tables

Appendix II - Useful References

Appendix III - Lab Panels

Appendix IV - Lab Load Interface (LLI) Tool

Case Report Forms for GVHD Studies

Changes to Case Report Forms since Last Version of the Manual

New Standard eCRFs

- Consults
- Extent of Disease (Neuro Oncology Branch)
- Pathology Report
- Storage

Updated eCRFs

Adverse Events

- · Serious instructions clarified.
- Added Expedited to Manufacturer.

Chimerism

• Specimen picklist updated.

Enrollment

- Gender picklist updated.
- Disease Term picklist using CTEP Simplified Disease Code list.

Extent of Disease

 eCRF broken into two: one for the Lesion Identifications and another for the Lesion Measurements.

Labs

• Added 2 new eCRF Lab Panels: HLA and Chimerism.

Off Study


• Removed Reason 'O' from Off study Reason Picklist used in studies that have Follow-up period.

General-Instructions

Data Entry Chronology

Case Report Forms should be created and completed in chronological order as follows:

- 1. Screening CRFs and any labs needed to support eligibility.
- 2. Each course in sequential order including:
 - Course Initiation
 - Study Medication Administration
 - Pharmacokinetics, if applicable
 - Physical Exam
 - Course Assessment
 - Any additional cycle specific CRFs.
- 3. At completion of patient's treatment, Off Treatment CRF.
- 4. If the protocol specifies a follow-up period after the treatment, complete the Follow-up and any other applicable follow-up CRF manually complete the labs CRFs done after the date off treatment since those will no longer be automatically loaded.
- 5. At end of study, when the follow-up period is completed, enter the Off Study CRF.
- 6. If the patient dies during treatment or follow-up period, complete the Survival, Off Treatment and Off Study CRFs.



Data Reporting

Complete the CRFs according to the protocol and in a timely manner. Studies reporting to CTMS submit data every two weeks. Studies reporting to CDUS submit data every three months. Other studies might have different reporting requirements.

Electronic Case Report Forms

An electronic CRF in Oracle Clinical is called a DCI - data collection instrument. In C3D, these CRFs always have three fields at the top:

- 1. Visit Date (see <u>#Entering Dates</u> below)
- 2. Blank check box (see #Blank Case Report Forms below)
- 3. Comments (see #Blank Case Report Forms below)

Below these fields, there are at least two tabs (also known as DCM - data collection module). For example: In the Prior Radiation CRF, the first tab is used to collect information about the patient's prior radiation treatments while the second tab is used to collect comments about the prior radiation treatments.

Blank Case Report Forms

Mark a complete CRF blank whenever there is no information to enter in it. For example: Place a check on the Prior Radiation CRF Blank check box to indicate that a patient has never received radiation treatment prior to enrollment. Optionally, enter some explanation, in the Comments field next to the Blank check box, to indicate why the entire CRF is blank.

Entering Comments

Each CRF has a section for entering multiple comments about the data entered in the CRF. This area is always the last tab in the CRF. Enter the date and the applicable comments.

Entering Dates

Ongoing CRFs: Visit date is an optional field (can be left blank).

Course-specific CRFs: Refer to each eCRF's instructions for specific directions on what must be entered as visit date. A visit date cannot be a partial date.



The current version of Oracle Clinical does not permit the removal or change of the label of the visit date.

Complete dates (day, month, year):

Entered in the U.S. format: month, day and year. That is the default date format in the Oracle Clinical RDC. Dashes (-) and slashes (/) do not need to be entered, simply the numbers. To enter the year in a century format use YYYY, since years higher than the current one default to the previous century. The recommended entry format for complete dates is: MMDDYYYY.

Partial dates (month and year or simply year):

Only acceptable in a few places such as baseline symptoms and patient's history.



- For year only, use 00-00-YYYY.
- For month and year, use 00-MON-YYYY.

Partial dates are not acceptable for dates that fall within the date of registration and date off study since the complete dates for events occurring during the study are known.



Future dates are not allowed.

Entering Time:

All times are to be recorded on a 24 hour clock. Enter 1:00 PM as 13:00 and midnight as 00:00.

Using Pick Lists

A pick list is a selection of acceptable values for a particular field. Once you place the cursor in the field where you will enter data, an ellipsis (...) is displayed to the right of the field which indicates there is a pick list available for you to use. Click on the ellipsis to display the pick list. Whenever possible, select from a pick list to assure accurate and consistent data entry. If a pick list does not contain the entry you need, type in the information. If the entry should be on the pick list or you are typing in a value that is not on the pick list repeatedly, request it to be added to the pick list.

Currently there are four pick lists that over one thousand items. C3D only lists the first thousand items. If the item need cannot be found because it is beyond the one thousand item, a search criterion must be specified before the pick list is displayed.

Ex: type in %odiu% and then display the pick list. This criteria searches for items that contain the lower characters odiu. Please note that the search is case sensitive and upper and lower cases will make a difference.

The four pick lists are:

- 1. Institutions present in Enrollment and Course Initiation CRF;
- 2. Disease Term present in the Enrollment CRF;
- 3. CTCAE Term present in the Baseline Symptoms and Adverse Events CRFs;
- 4. Agents present in the Concomitant Measures and Medications CRFs.

Mandatory Fields

Some fields in a CRF are defined as mandatory. That means information must be entered in them when the form is created. Each CRF instruction sheet will identify mandatory items in Field Descriptions and Instructions table.

Inserting Unplanned Visits

In a C3D Study, all the necessary visits and CRFs are planned according to the Protocol Schema. Each CRF has a limited amount of data that can be entered. If this limit is reached, a new CRF needs to be used. This is done by inserting an unplanned visit which creates placeholders for all CRFs in that visit. **H** ere are the steps:

- 1. Select the visit which has the CRF
- 2. From the C3D menubar, select the menu option 'Insert'
- 3. Then select the menu option 'Visit'

A new unplanned visit is added to the right of the existing one and includes all CRFs planned for such visit. Enter data in the new CRFs as usual.

When unplanned visit have been added, the right most column in a visit is 'Show unplanned pages'. Clicking on it will reveal the unplanned CRFs.

Each Lab Panel has its own visit, but only one CRF is planned. Any additional CRF must be manually created by inserting an unplanned visit. That is common when entering outside labs. Labs electronically loaded into C3D automatically insert the necessary unplanned visits.

The Ongoing visit is another one where, over time, an unplanned visit might be necessary to capture additional data on Adverse Events, Concomitant Measures and Medications

Adverse Events

Contents

- Purpose
- Adverse Events eCRF
- Field Descriptions and Instructions
- Validations
- Derivations

Purpose

This eCRF is an ongoing form to capture all adverse events experienced by the patient regardless of the course.

An adverse event is any unfavorable or unintended sign, including abnormal laboratory findings, symptom or disease having been absent at baseline, or if present at baseline, appears to worsen, that has a temporal association with a medical treatment or procedure regardless of the relationship of the event to the medical treatment or procedure.

All adverse events will be coded using protocol specific version of NCI Common Terminology Criteria for Adverse Events (CTCAE) version. Every attempt to code the adverse event to a term using the standard terminology will be made before selecting the "other" term in a category.

Record all adverse events experienced by the patient, including laboratory abnormalities, regardless of relationship to the study medication.

An adverse event entry is composed of both the adverse event term plus the grade. Complete a separate row for each adverse event entry to be recorded using the appropriate adverse event term and the appropriate codes for "grade", "attribution(s)", "serious", "action", "therapy", and "outcome" in the respective column for each event.

If an adverse event has not been resolved, leave the Resolved Date blank. The Resolved Date can be filled at a later time when the adverse event is considered resolved. Resolution means a change in grade to a higher or lower grade.

If a patient died on study then the death adverse event onset and resolved dates should be the same.

✓ How to record baseline symptoms that change, either improve or worsen:

If a pre-existing condition resolves, it does not need to be reported as an adverse event since it would have been already recorded on the Baseline Symptoms case report form. Enter the resolution date on the corresponding symptom entry on the Baseline Symptoms case report form improves, no entry is made on the AE eCRF. See BL eCRF for instructions.

If a pre-existing condition worsens (i.e.: the grade of the baseline symptom increases), that constitutes an adverse event entry which must be reported in full detail.

If a pre-existing condition improves without a resolution, do not enter as an Adverse Event. When it resolves, enter the resolution date on the corresponding symptom entry on the Baseline Symptoms case report form.

Adverse Events eCRF

Authorities See See See See See See See See See S	See (20,200,201,01)	Patient ST Page 12 446 Event for Original Page 1 of 1, Report 1 of 1.	Vertical Acc Acc
	County's Times first and a final part of the county's the		Serius Adias Ti

The second screen shot is the portion to the right of the Grade The third screen shot is the portion to the right of the DLT

Field Descriptions and Instructions

Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Prior Course Adverse Event field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number that this adverse event started in as derived from the course initiation start date.Late adverse event (For CTMS and CDS monitored studies, it means the adverse event observed after the date of off treatment) have no associated Course #.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course that this adverse event started as derived from the course initiation start date.	5 digits

Prior Course Adverse Event (c)	For adverse events that begin on the first day of a course, indicate if related to the prior course by entering: • Y- Related to a prior course • N- Not related to a prior course For an adverse event that begins on the first day of the course PRIOR to any study medications being given, select "Y". For an adverse event that begins on the first day of the course AFTER study medications have been given, select "N". • Note: This field is optional for non-CTEP sponsored studies.	Use pick list.
Date of Onset ^(m)	Enter the date of first observation of the adverse event and grade. i If a patient died on study then start date and the resolve date for the death AE should be the same.	DD-MMM-YYYY
Date Resolved	Enter the date of resolution of the adverse event and grade. Leave this field as well as the Outcome field blank if the adverse event is ongoing. Resolution means a change in grade to a higher or lower grade.e.g, to the normal grade (grade zero) or the return to the baseline symptom grade.	DD-MMM-YYY

CTC Term (m)

Using the pick list to select a CTCAE (Common Terminology Criteria for Adverse Events) Term. In the absence of a specific adverse event term, choose the "Other" term from the appropriate general category and be sure a meaningful adverse event description is entered in the "adverse event description" field.

Use pick list.

Note: This pick list does not show all the CTCAE Terms. User must type in a search criterion and then click on the ellipsis perform the search and display the resulting matched CTCAE Terms. Ex: type %ypo% to list all the terms that include the lower characters 'ypo' somewhere in the CTCAE Term.

Note: Visit
 CTEP's CTCAE
 webpage for
 latest version.

System Organ Class (d)

Broad classification of adverse events based on anatomy and/or pathophysiology. Within each category there is the adverse event term/description.

Note: This field is derived from the selected CTC Term 40 Characters

Adverse Event Description

Enter a succinct clinical description of the adverse event.

1 Note: This field is mandatory, unless thelor} CTCAE term is the same as the description (e.g. nausea, diarrhea).

DO NOT enter raw data (i.e.: lab result). Use the term increase or decrease.

DO NOT enter the attribution in this field. Use the Attribution field for this purpose.

100 characters(Only 33 characters are reported for CTMS monitored studies.)

Grade (m)

Grade adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version indicated in the protocol.

 Note: Note: Some grades are disallowed for some categories in the CTCAE. In the CTCAE tables this will be noted by the use of an em-dash "-". For example, Hair loss/Alopecia can only be graded as a 1 or 2, so grade 3, 4, and 5 do not exist and will be noted in the table with a "-" verses a description.

If the protocol does not use either CTC or CTCAE, grade according to the following general criteria:

- 1. Mild barely noticeable, does not influence functioning
- 2. Moderate makes subject uncomfortable, influences functioning
- 3. Severe severe discomfort, treatment given
- 4. Life threatening immediate risk of death
- 5. Fatal causes death of the patient - Outcome must be 4-Died

Use pick list.

Attribution to Research Evaluate the adverse event's Use pick list. relationship to the subject's participation in the study, including study-related therapy and procedures. Select one of the following codes to record this evaluation: • 1. Unrelated - clearly not related • 2. Unlikely - doubtfully related • 3. Possible - may be related • 4. Probable - likely related • 5. Definite - clearly related Note: Attribution to Research must be the same as the highest Attribution to IND, IDE, Commercial, Surgery and Radiation. Attribution to IND (m) Evaluate the adverse event's Use pick list. relationship to the investigational agent. Select one of the following codes to record this evaluation: 1. Unrelated - clearly not related • 2. Unlikely - doubtfully related • 3. Possible - may be related • 4. Probable - likely related • 5. Definite - clearly related Attribution to IDE Evaluate the adverse event's Use pick list. relationship to the investigational device exemption. Select one of the following codes to record this evaluation: • 1. Unrelated - clearly not related 2. Unlikely - doubtfully related • 3. Possible - may be related • 4. Probable - likely related • 5. Definite - clearly related 1 Note: This field is optional for some studies.

Attribution to Commercial Evaluate the adverse event's Use pick list. relationship to the commercial agent. Select one of the following codes to record this evaluation: 1. Unrelated - clearly not related • 2. Unlikely - doubtfully related • 3. Possible - may be related • 4. Probable - likely related • 5. Definite - clearly related Note: This field is optional for some studies Attribution to Radiation Evaluate the adverse event's Use pick list. relationship to the Radiation therapy. Select one of the following codes to record this evaluation: • 1. Unrelated - clearly not related • 2. Unlikely - doubtfully related • 3. Possible - may be related • 4. Probable - likely related • 5. Definite - clearly related Note: This field is optional for some studies. Attribution to Surgery Evaluate the adverse event's Use pick list. relationship to the surgery. Select one of the following codes to record this evaluation: • 1. Unrelated - clearly not related • 2. Unlikely - doubtfully related • 3. Possible - may be related • 4. Probable - likely related • 5. Definite - clearly related Note: This field is optional for some studies.

Attribution to Disease	Evaluate the adverse event's relationship to the disease. Select one of the following codes to record this evaluation: 1. Unrelated - clearly not related 2. Unlikely - doubtfully related 3. Possible - may be related 4. Probable - likely related 5. Definite - clearly related Note: This field is optional for some studies.	Use pick list.
Attribution to Other	Evaluate the adverse event's relationship to other causes not listed above. Select one of the following codes to record this evaluation: 1. Unrelated - clearly not related 2. Unlikely - doubtfully related 3. Possible - may be related 4. Probable - likely related 5. Definite - clearly related Note: This field is optional for some studies	Use pick list.
Other, Specify	Enter an explanation when 'Attribute to Other' is selected.	40 Characters
Unexpected? ^(m)	Indicate if the adverse event is unexpected as defined by the NCI IRB, by entering: • Y- Yes • N- No	Use pick list.

DLT (m) Indicate if the adverse event is dose Use pick list. limiting, as defined in the protocol, by entering: • Y- Yes • N- No 1 Note: Refer to the protocol for the definition of a dose limiting toxicity which should include the grade of the events and the duration of the event. Note: Mandatory for

Phase I Clinical Trials. Serious (m)

Indicate if the adverse event was a "serious" event by selecting from the following codes, as per the Code of Federal Regulations 21 Part 312. If multiple categories are applicable, select the worst.

- 1. Not a Serious Adverse Event
- 2. Life-Threatening Event An adverse event or suspected adverse reaction is considered "life-threatening" if, in the view of either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, might have caused death.
- 3. Death
- 4. Disability Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- 5. Hospitalized Inpatient hospitalization or prolongation of existing hospitalization
- 6. Congenital Anomaly -Congenital anomaly/birth defect
- 7. Important Medical Event
 -Important medical events that
 may not result in death, be
 life-threatening, or require
 hospitalization may be
 considered serious when, based
 upon appropriate medical
 judgment, they may jeopardize
 the patient or subject and may
 require medical or surgical
 intervention to prevent one of the
 outcomes listed in this definition.

Use pick list.

Action (m) Indicate any changes made to the Use pick list. study regimen in response to the adverse event using the following codes. "Action" refers to the decision to reduce or continue the i nvestigational medication. • 1. None • 2. Dose Reduced • 3. Regimen Interrupted • 4. Therapy Discontinued • 5. Interrupted & Reduced If the "Action" for any adverse event is recorded as 2, 3, 4, or 5, the changes in medication administration must be reflected on the Study Medication Administration form. Note: Interrupted also means therapy was delayed. Therapy (m) Indicate if additional therapy is Use pick list. required to treat the adverse event. • 1. None • 2. Symptomatic (i.e.: required medications to treat event) • 3. Supportive (i.e.: required medications and/or IV fluids, blood products) • 4. Vigorous Supportive (i.e.: required surgery, intubation)

A corresponding entry of the therapy given to treat the adverse event must be recorded on the

Measures/Medication form.

Concomitant

Outcome

Select the final status of the patient when the adverse event is considered "resolved".

- 1- Recovered the event (CTCAE term + grade) has resolved to normal or changed to a lower or higher grade. The recovery may be due to the suspension of study treatment or due to concomitant treatments that have ended.
- 4- Died Record outcome of death only for adverse events that resulted in the patient's death.

Note: For ongoing adverse events, leave this and the Resolution Date fields empty.

1 Note: For deaths on study, only the events which caused the death should have the outcome coded as a "4." The events that were still continuing at the time of the death would still be ongoing. Do not enter a resolved date, and outcome.

Use pick list.

Expedited Report to IRB (m)

Indicate if an expedited adverse event report was sent to IRB by entering:

- Y- Yes
- N- No

Use pick list.

Expedited Report to Sponsor (m)	Indicate if an expedited adverse event report was sent to sponsor by entering: • Y- Yes • N- No For CTEP-sponsored studies, this means that an expedited adverse event report was sent to CTEP via CTEP's Adverse Event Expedited Reporting System (AdEERS). • Note: This field is optional for some studies.	Use pick list.
Expedited Report to FDA ^(m)	Indicate if an expedited adverse event report was sent to FDA by entering: • Y- Yes • N- No For studies where the PI holds the IND, this means that the PI has sent an IND Safety Report to FDA. • Note: This field is optional for some studies.	Use pick list.
Expedited Report to OBA ^(m)	Indicate if an expedited adverse event report was sent to OBA (Office of Biotechnology Activities) by entering: • Y- Yes • N- No i Note: This field is optional for some studies.	Use pick list

Expedited Report to Manufacturer (m)	Indicate if an expedited adverse event report was sent to Manufacturer by entering:	Use pick list
	Y- YesN- No	
	Note: This field is optional for some studies.	

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Validations

Code	Description	Resolutions
AE01	Date Resolved is before Date of Onset.	Correct either the Date of Onset or Date Resolve.
AE03	Two Adverse Event records have identical values for Date of Onset, CTC Term and Grade.	If duplicate, delete one of the records. If not, manually resolve the discrepancy.
AE04, AE05, AE06, AE07	Two Adverse Event records with the same CTC Term and/or Description have overlapping Date of Onset and Date Resolved ranges.	Correct the Onset and Resolution Dates for the Adverse Events in question or review/correct the CTC term/description
AE08	Adverse Event Description missing for some certain CTC terms that require a clinical description.	Enter the Adverse Event Description or review/correct the CTC term/description.
AE09	A Baseline Symptom exists with the same CTC term and Grade as the Adverse Event and the Baseline Symptom has not been resolved.	Verify the Baseline Symptom resolution date, the Adverse Event onset date, or CTC Term. An Adverse Event with the same grade and CTC Term as the Baseline Symptom is only acceptable when the Baseline Symptom has been resolved and the AE onset date is after the Baseline Symptom resolution date.

AE10	The CTC Term for the ongoing Adverse Event has a specified lab, but a lab record with lab date = AE onset date and lab grade = AE grade does not exist.	Verify that the Averse Event is supported by appropriate lab test result.
AE11	Adverse Event is resolved and there is no supporting lab test result.	Review Adverse Event and related lab test result and their grades. A supporting lab result is one with the same date as the Adverse Event resolution date but with a different grade.
AE14, AE15	The Adverse Event Date of Onset or Date Resolved is in the future.	Correct the Onset or Resolution Dates. No future dates should be recorded.
AE16	The Adverse Event Date of Onset is less than the first Course Start Date.	Correct the Adverse Event Date of Onset to be equal to or after the first Course Start Date.
AE17	The Adverse Event CTC Grade is invalid.	Enter a Grade that is permissible for the CTC Term.
AE19	Resolution date has been entered, but Outcome is not provided or vice-versa.	A Date Resolved must be accompanied by an Outcome and vice-versa.
AE20	Adverse Event is the cause of death but Grade is not 5-Fatal and/or Outcome is not 4-Died and/or Seriousness is not 3-Death.	Change the Adverse Event Grade, Outcome and Seriousness.
AE21	Prior Course checked 'Y', but there is no Course with a Start Date the same as the Adverse Event Onset Date.	Change the Adverse Onset Date, the Prior Course or the Course Initiation Start Date.
AE22	Adverse Event 'Attribute to Other' and 'Other, Specify' are not present together.	Enter 'Other, Specify' if 'Attribute to Other' is associated.
AE23	Adverse Event Attribution to Research is not the same as the highest Attribution to IND, IDE, Commercial, Surgery, and Radiation	Review all Attributions to make sure that Attribution to Research is same as the highest Attribution to IND, IDE, Commercial, Surgery and Radiation.

Derivations

Code	Field Name	Description
AE1002	Course #	Course number is derived based on the course initiation start dates.
AE1003	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date.
AE1004	CTC Category	Broad classification of the CTC Adverse Event Term derived from the pick list selection.

Baseline Medical History

Contents

- Purpose
- Baseline Medical History eCRF:
- Field Descriptions and Instructions
- Validations

Purpose

Record a brief description of major medical and surgical events during the patient's lifetime, excluding the events related to their cancer therapy.

Screening Physical Exam findings should be entered on the Screening Physical Exam eCRF.

Baseline Medical History eCRF:





Field Descriptions and Instructions

Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the date the form was completed (i.e. the date information was gathered).	DD-MMM-YYYY
Date of Examination^(m)^	Enter the date that the patient was examined and the medical history was documented. Since only one Baseline Medical History form is used, if the information has been assembled over a period of time, enter the date of the latest examination.	DD-MMM-YYYY

Body System	Predefined Body System. It cannot be changed.	text
Finding Results^(m)^	Indicate whether the finding results for the particular body system were either: N - Normal A - Abnormal Z - Not Assessed L - Not Applicable Comments are required for abnormal finding results.	5 digits
	select 'Normal" if the body system was not specifically assessed (i.e.: not mentioned in the progress note in the medical record). 'Not Assessed' means a discussion on the body system was not raised or the body system was not assessed.	
Medical History if Abnormal	Enter a brief description of major medical and surgical events during the patient's lifetime (i.e.: hypertension under cardiovascular, appendectomy as child under abdomen). Enter the history for the appropriate body system to which the information refers. For "Other" indicate the body or organ system in the history.	128 characters



Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Validations

Code	Description	Resolutions
------	-------------	-------------

MH01	Date of Examination is in the future.	Enter a date that is earlier or equals to the current date.
MH02	Date of Examination is after the first Course Initiation Start Date.	Review the Date of Examination and/or the first Course Initiation Start Date.
MH03	'Finding Result's is marked abnormal and 'Medical History if Abnormal' details were not provided.	Enter the details of the 'Medical History if Abnormal' or change the 'Finding Results' selection.
MH04	'Medical History if Abnormal' details were specified and 'Finding Results' is not marked abnormal.	Change the 'Finding Results' to abnormal or remove the provided 'Medical History if Abnormal' details.

Baseline Symptoms

Contents

- Purpose
- Baseline Symptoms eCRF:
- Field Descriptions and Instructions
- Validations
- Derivations

Purpose

Record the patient's baseline symptoms prior to starting treatment.

Baseline Symptoms are symptoms that are present when the patient starts treatment (e.g., Cycle 1 Day 1 pre-dosing). These are not symptoms that occurred and resolved between the time screening studies/exams/procedures are done and Day 1/pre-treatment. For those symptoms, consider adding to Medical History.

Baseline Symptoms eCRF:





Field Descriptions and Instructions

Field Name	Description / Instructions	Format
------------	----------------------------	--------

Visit Date ^(m)	Enter the date the form was initiated.	DD-MMM-YYYY
	Note: If a new baseline symptom is revealed once treatment has begun, do not change the visit date. Record the new symptom information in the appropriate fields as indicated below.	
Date of Onset ^(m)	Enter the date that the symptom was first observed/experienced.	DD-MMM-YYYY, MMM-YYYY
Date Resolved	Enter the date the baseline symptom was resolved.(i.e.: no longer exists at any grade).	DD-MMM-YYYY

CTCAE Term^(m)

Use the pick list to select a CTCAE (Common Terminology Criteria for Adverse Events) Term.

Use pick list.

1 Note: This pick list does not show all the CTCAE Terms. User must type in a search criterion and then click on the ellipsis perform the search and display the resulting matched CTCAE Terms. Ex: type %ypo% to list all the terms that include the lower characters 'ypo' somewhere in the CTCAE Term.

Note: Visit
CTEP's CTCAE
webpage for
latest version.

System Organ Class^(d)

Broad classification of adverse events based on anatomy and/or pathophysiology. Within each class there is the adverse event term/description.

Note: For studies using CTCAE version 3.0, this field is 'CTC category'. This field is derived from the selected CTCAE Term.

40 Characters

Symptom Description	Enter a succinct clinical description of the symptom. i Note: This field is mandatory for 'Other, Specify' CTCAE terms. For example: Immune system disorders - Other (Specify,). i It might be also used to further describe symptom such as "Eye pain" by entering "Left eye".	100 characters(Only 33 characters are reported for CTMS monitored studies.)
Grade ^(m)	Enter the severity of the symptom by using the protocol's specified CTCAE Version. If the symptom is not explicitly mentioned it should be coded in the appropriate "other" category and graded according to the general criteria: 1. Mild – barely noticeable, does not influence functioning 2. Moderate – makes subject uncomfortable, influences functioning 3. Severe – severe discomfort, treatment given 4. Life threatening – immediate risk of death	Use pick list.
Related to Disease? ^(m)	Indicate whether or not the symptom is related to the study disease by selecting one of the following options: Y- Yes N- No U- Unknown	Use pick list.

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Validations

Code	Description	Resolutions
BS01	Date of Onset is in the future.	Enter a Date of Onset that is equal or earlier than the current date.
BS02	Baseline Symptom CTC/CTCAE Term Grade is not valid or is missing.	Select a Grade from the pick list.
BS03	Resolved Date is prior to Date of Onset.	Resolved Date must be after or equals to the Date of Onset.
BS10	Symptom Description missing for CTCAE Term that requires a description. (Allergy/Immunology - Other (Specify,))	Enter a Symptom Description for the corresponding CTCAE Term.

Derivations

Code	Field Name	Description
BS1001	System Organ Class(SOC)	Broad classification of the CTC Adverse Event Term derived from the pick list selection.

Cardiac


Purpose

Record the patient's cardiac ejection fraction.

Contents

- Purpose
- Cardiac eCRF:
- Field Descriptions and Instructions
- Validations
- Derivations

Cardiac eCRF:



Field Descriptions and Instructions

Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the start date of the first course in this field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number the cardiac ejection fraction results are related to based on their date and time.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course the cardiac ejection fraction results are related to based on their date and time.	5 digits
Evaluation Date ^(m)	Enter the date the procedure was performed.	DD-MMM-YYYY

Evaluation Time ^(m)	Enter the time the procedure was performed.	HH(24):MM
Procedure ^(m)	Select on of the following procedures from the pick list: • MUGA • MRI • Echocardiogram • Cardiac Catheterization. • Nuclear stress test.	Use pick list.
Pre-Ejection Period	Enter the Pre-Ejection Period.	8 digits and 3 decimals
LV Ejection Time	Enter the Left Ventricular Ejection Time.	4 digits
LV Ejection Fraction (%) ^(m)	Enter the Left Ventricular Fraction percentage.	3 digits

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Validations

Code	Description	Resolutions
CAR01	Evaluation Date is in the future.	Enter a date that is equal to or prior to the current date
CAR02	Check for duplicate Cardiac evaluation entries – Same Date, Time and Procedure.	Correct the Evaluation Date, Time and Procedure.

Derivations

Code	Field Name	Description
CAR1001	Course #	Course number is derived based on the course initiation start dates and the Evaluation Date.
CAR1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the Evaluation Date.

Chimerism


Contents

- Purpose
- Chimerism eCRF:
- Field Descriptions and Instructions
- <u>Validations</u>
- Derivations

Purpose

Record the transplant date and related pre and post test results.

Chimerism eCRF:





Field Descriptions and Instructions

Field Name	Description / Instructions	Format
Visit Date ^(m)	Date the first test was performed.	DD-MMM-YYYY
Date of Transplant ^(m)	Date the transplant was performed.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number the test is related to based on their date and the Course Initiation start dates.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course the test is related to based on their date and the Course Initiation start dates.	5 digits

Day in Course ^(d)	Enter the time the procedure was performed.	HH(24):MM
Date of Test ^(m)	Date the test was performed	DD-MMM-YYYY
Time of Test	Time the test was performed.	HH(24):MM
Days Post Transplant ^(d)	Number of days before or after the transplant that the test was done. It will be a negative number if test was done before the transplant.	5 digits
Specimen ^(m)	Select a specimen from the pick list. A- Apheresis Cells B- Whole Blood C- CSF D- CD33 Myeloid Cells L- CD33 Lymphoid Cells M- PBMC O- Bone Marrow P- Plasma S- Serum T- Tumor Tissue U- Urine V- Saliva Y- CD14/15 Myeloid	Use pick list.
Result (%) ^(m)	Test results in percentage.	12 digits and 5 decimal
Comments	Enter comments applicable to the test.	200 characters

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Validations

Code	Description	Resolutions
CHM01	Duplicate Specimen, Date of Test and Time of Test.	A Specimen must have a unique Date of Test and Time of Test. Review the Specimen and/or the Date of Test and Time of Test.
CHM02	Result (%) is out of range.	Result % must be between 0 and 100%.

Derivations

Code	Field Name	Description
CHM1001	Course #	Course number is derived based on the course initiation start dates and the Date of Test.
CHM1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the Date of Test.
CHM1003	Days Post Transplant	Number of days before or after the transplant that the test was done. It will be a negative number if test was done before the transplant.

Concomitant Measures and Medications

Contents


- Purpose
- Concomitant Measures / Medications eCRF
- Field Descriptions and Instructions
- Validations
- Derivations

Purpose

Record all concomitant medications, including therapies given to treat adverse events.

If a patient is taking a medication PRN, do not use a separate line for each time the medication is taken, instead report the first and last dates taken.

Concomitant Measures / Medications eCRF





Field Descriptions and Instructions

Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Start Date field.	DD-MMM-YYYY
Course # (d)	Indicates the course number that this concomitant measure / medication started in as derived from the course initiation start date.	5 digits

Day in Course (d)	Indicates the day since the beginning of course that this concomitant measure / medication started as derived from the course initiation start date.	5 digits
Start Date ^(m)	Enter the start date of the measure or medication. Note: Partial date is only acceptable for baseline measure or medication.	DD-MMM-YYYY or MMM-YYYY
Stop Date	Enter the stop date of the measure / medication. Note: Partial date is only acceptable for baseline measure or medication.	DD-MMM-YYYY or MMM-YYYY

Agent Name

In the case of agents, state the generic name of the medication administered, or, in the case of combinations such as trimethoprim / sulfamethoxazole, state the brand name (i.e., Bactrim).

1 Note: This pick list does not show all the Agents. User must type in a search criterion and then click on the ellipsis perform the search and display the resulting matched Agents. Ex: type %ydro% to list all the agents

that include the lower characters

somewhere in the agent's name.

'ydro'

Note: Pre and post medications specified in the protocol and administered as part of the patient's treatment, must be entered in the Study Medication Administration case report form.

Note: Do not select an agent name if a procedure has been entered.

Use pick list.

Procedure /Measure If a procedure/measure, state e.g., Use pick list. oxygen administration, pleural tapping, etc. Note: Do not select a procedure if an agent name has been entered. Dose (m) For CTMS studies, enter the total 100 characters daily dose of the agent. For non-CTMS studies, enter the dose of the agent as appropriate. 1 Note: This field is mandatory for agents. If a procedure/meas ure, leave blank. In the case of combinations such as Bactrim, enter: For CTMS studies: the total number of combination tablets taken daily. Ex: Dose 2, Unit tab, schedule bid. For non-CTMS studies: the single dose. Ex: Dose 1, Unit tab, schedule bid. When the schedule is PRN (For example: taking 2 tabs of Percocet PRN every four hours) enter: For CTMS studies: the maximum possible dose in a 24-hour period. Ex: Dose 12, Unit tab, q4hr PRN.

For non-CTMS studies: the single

Ex: Dose 2, Unit tab, q4hr PRN.

dose.

UOM	Select the total daily dose units of measurement. Note: If a procedure/meas ure, leave blank.	Use pick list.
Schedule	Enter the frequency of medication administration or measure under schedule.	24 characters
Route	Select the route given: IM - intramuscular ID - intradermal IV - intravenous bolus (less than 30 minutes) IVI - intravenous infusion (greater than 30 minutes, but less than 24 hours) CIV - continuous intravenous infusion (greater than 24 hours) IA - intra-arterial IT - intrathecal IP - intraperitoneal IH - intrahepatic IHI - intrahepatic infusion SC - subcutaneous T - topical PO - oral RT - radiation	Use pick list.
Reason ^(m)	Select the reason the medication is being administered or why measure done. For example, if Bactrim is being given as a prophylactic, select "pneumocystis prophylaxis". Note: Do not enter the pharmacological classification of the medication (e.g. antibiotic, analgesic, etc.)	Use pick list.

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
CM01	Agent and Procedure are missing.	An Agent or Procedure must be present.
CM02	Both Agent and Procedure are filled.	Agent and Procedure cannot be both selected at the same time.
CM03	Stop Date is before the Start Date.	Stop Date must not be earlier than Start Date.
CM04	Agent entered and Dose and/or Units of Measurement are/is missing.	If Agent is entered, Dose and Unit of Measurement must be present.
CM05	Dose and/or Unit of Measurement entered and Procedure also entered.	If Procedure is entered, Agent, Dose and Unit of Measurement must not be present.
CM06, CM07	Start and/or Stop Date are/is in the future.	Enter a date that is equal to or prior to the current date.
CM10, CM11	Partial Start Date and/or Stop Date are/is after the first Course Initiation Date.	Partial Start and Stop Dates are only acceptable for baseline measures and/or procedures.
CM12	Dose is not a valid numeric value.	Enter a valid numeric value.

Derivations

Code	Field Name	Description
CM1001	Course #	Course number is derived based on the course initiation start dates and the concomitant measure / medication start date.
CM1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the concomitant measure / medication start date.

Consults


Contents

- <u>Purpose</u>
- Consults eCRF
- <u>Validations</u>

Purpose

Record all ...

Consults eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Lesion # field.	DD-MMM-YYYY
Evaluation Date		DD-MMM-YYYY
Consult Evaluation Type		Use pick list.
Notes		200 characters

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

CON?	?	?

Course Assessment


Contents

- Purpose
- Course Assessment eCRF
- Field Descriptions and Instructions
- Validations
- Derivations

Purpose

Record the course assessment information when the course is completed, and the patient is evaluated or taken off treatment.

Course Assessment eCRF



Field Descriptions and Instructions

Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the date the course started.	DD-MMM-YYYY
Start Date of Course^(d)^	Shows the Start Date of Course entered in the Course Initiation case report form.	DD-MMM-YYYY

Dose change from TAC entered on Indicate if the patient's treatment Use pick list. Course Initiation CRF^(m)^ was different from that specified by the Treatment Assignment Code (TAC) for this course as entered on the Course Initiation CRF. If the treatment was different, indicate whether this was planned or unplanned, and record the reason, e.g. dose reduction due to toxicity, on the Comments tab of this CRF. Note: optional for non-CTEP sponsored studies. 1 - Yes, Planned - change in treatment had been decided before the start of the course, e.g., due to toxicity on a previous course. 2 - Yes, Unplanned - change was not intended at the start of the course, e.g., shortening the course (and thus lowering the dose level) due to adverse events or if there was a drug administration error. 3 - No - patient received the treatment specified in the Course Initiation TAC 9 - Unknown - only when the actual treatment cannot be determined, e.g., when the patient is uncooperative in reporting self-administration of study medication. Course Disposition^(m)^ A "completed" course is one that Use pick list. has been conducted in accordance with the protocol with respect to length including the observation period (two day variance allowed). A course is regarded as "discontinued" if it was shorter than specified in the protocol. Select one of the following values: Comp- Completed Dis- Discontinued Response Assessment^(m)^ Use pick list. Select the patient's best disease state as assessed during the course. This determination must be adequately documented in the patient's medical record.

NE - Not Evaluable - State the reason in the "Response Note" field.

NA - Not Assessed - State the reason in the "Response Note" field.

NP - Protocol does not require a response assessment during the specific course.

TE - Too Early to confirm a response.

CRU - Complete Response Unconfirmed – Complete response assessed but not confirmed as per protocol timeframe.

Unless the protocol includes specific response evaluation criteria, the following guidelines should be observed:

CR - Complete Response - There is a disappearance of all evidence of disease as assessed relative to the baseline at start of treatment, not to previous courses. They must be confirmed by repeat assessments to demonstrate a disappearance of all evidence of disease.

PR or MR - Partial Response or Marginal Response - Response is assessed relative to the <u>baseline at start of treatment</u>, not to previous courses. They must be confirmed by repeat assessments. Subsequent evaluations at which tumor sizes are substantially unchanged should be assessed again as the same PR/MR.

PD - Progressive Disease - Response relative to the <u>best</u>

disease status (smallest tumor measurement) since treatment began. Thus a tumor re-growth after a PR would be assessed as PD not an MR. A PR or MR cannot follow a complete response "CR".

SD - Stable Disease - Tumor growth or shrinkage since the start of treatment is not enough to justify a CR/PR/MR response or a PD progression. Once an actual CR/PR/MR response or PD progression has occurred, an SD assessment is not valid.

DU - Disease Unchanged - Patient's disease is unchanged relative to the previous assessment. This code may be used when a CR/PR/MR/PD response is not merited but SD is inappropriate.

For protocols not using RECIST criteria in assessing response, the following might be applicable to use. Consult/follow protocol for definition and usage criteria.

MX - Mixed Response

RP - Response

NR - No Response

*RECIST:*Many protocols specify that the following <u>RECIST</u> criteria be used in assessing response.

Please use the following selections when assessing response using RECIST criteria only.



Note: CTEP's link to an article in the European Journal of Cancer: New response evaluation criteria in solid tumors: Revised **RECIST** guideline (version 1.1) guideline (version 1.1)

Evaluation of target lesions:

CR - Complete Response - Disappearance of all target lesions.

PR - Partial Response At least a 30% decrease in the sum of the LD (longest dimension) of target lesions, taking as reference the baseline sum LD.

PD - Progressive Disease - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded startedon study (this includes the baseline sum if that is the smallest on study) or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

SD - Stable Disease - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.

Evaluation of non-target lesions:

CR - Complete Response -Disappearance of all non-target lesions and normalization of tumor marker level

NON-CR/NON-PD - Non Complete Response and Non Progressive Disease - Persistence of one or more non-target lesion(s) and/or maintenance of tumour marker level above the normal limits.

Non-CR/Non-PD is preferred over 'Stable Disease' for non-target disease since SD is increasingly used as endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.

PD - Progressive Disease -Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Response Notes	Enter the reason why the Response Assessment is Not Evaluable (NE) or Not Assessed (NA). Some examples could include: protocol not followed, poor quality of scan, patient already treated.	32 characters
Date of Response	Enter the date of the earliest evaluation which, upon confirmation, justifies an assessment of CR, PR, MR, or SD/DU. This date will be the same date as the scan, or other method of disease assessment. For NE, record the date the patient's disease was assessed and deemed to be Not Evaluable. i Note: The original date of onset of response should be used for responses that persist through several courses.	DD-MMM-YYYY
Date of Progression	Enter the date of the evaluation used to determine the patient's disease status of progressive disease. Enter a date of progression if the disease progression occurred after an assessed better response (i.e. PR, CR, SD).	DD-MMM-YYYY

Any Adverse Events in this Course? (m)	Select "Yes" if any adverse event has occurred during this course. This includes adverse events with onset date belonging to a previous course that resolved during this course or that remain ongoing at the conclusion of this course. Select "No" if no adverse events occurred during this course. Note: The event(s) must be recorded on the Adverse Events case report form.	Use pick list.
--	--	----------------

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
CAS02, CAS03	Date of Response or Onset Date of Progress must not be future dates.	Change the date to a value no later than the current date.
CAS05	Response Notes entered and Response Assessment is different than "Not Evaluable" and "Not Assessed".	Remove the Response Notes if Response Assessment is different than "Not Evaluable" and "Not Assessed". Otherwise change the Response Assessment to "Not Evaluable" and "Not Assessed".
CAS06	Response Assessment is "Not Evaluable" or "Not Assessed" and no Response Notes were entered.	Enter the Response Notes if Response Assessment is "Not Evaluable" or "Not Assessed". Otherwise change the Response Assessment to a selection other than "Not Evaluable" and "Not Assessed".
CAS07	Date of Response is required when Response Assessment is CR, PR, MR, SD, or DU.	Enter the Date of Response or Review the Response Assessment.
CAS08	Date of Progression is required when Response Assessment is PD.	Enter the Date of Progression or Review the Response Assessment.

CAS09	Course Assessment marked as having adverse events, but there are no adverse events with an onset date that falls within this course start and end dates.	Change the field "Any Adverse Events in this Course?" to "NO" if no related adverse events exist. Otherwise enter the appropriate adverse events or adjust the appropriate adverse events dates.
CAS10	Course Assessment marked as not having adverse events, but there is at least one adverse event with an onset date that falls within this course start and end dates.	Change the field "Any Adverse Events in this Course?" to "YES" if the related adverse events are appropriate. Otherwise remove the adverse events or correct the adverse events dates.

Derivations

Code	Field Name	Description
CAS1001	Start Date of Course	The Start Date of Course entered in the Course Initiation case report form.
CAS1002	End Date of Course	The day before the start date of the following course or the off treatment date.

Course Initiation

Contents

- Purpose
- Course Initiation eCRF
- Validations
- Derivations

Purpose

Record course initiation Start Date, Arm, Treatment Assignment Code (TAC) and Treating Institution.

Course Initiation eCRF





Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the course started.	DD-MMM-YYYY
Course # ^(d)	Sequential number of this course of treatment: first course = 1, second course = 2, etc.	5 digits
Start Date of Course ^(m)	Enter the date on which the course was started. This is the date on which a protocol stipulated medication (or treatment) was first administered.	DD-MMM-YYYY

Arm ^(m)	Select the "Arm" of the protocol-specific treatment regimen the patient is to receive, as designated in the activation letter.	Use pick list.
	Note: Only mandatory for CTMS monitored, CTEP - sponsored studies.	
Treatment Assignment Code ^{(m)(c)}	Select the appropriate code for the patient's treatment assignment as specified. For non-CTEP studies, "Treatment Assignment" codes are based on the treatment schedules described in the protocol. Please contact the Informatics team for advice on TAC formulation and modification. For CTEP sponsored studies, "Treatment Assignment" codes are provided by CTEP to the investigator, in the form of a coding letter, at the time of protocol approval, and are updated as required following approval of protocol amendments. Advice on TACs is available from the CTEP's Protocol and Information Office (pio@ctep.nci.nih	Use pick list.

Treating Institution^(m)

Select the unique CTEP institution code where the patient actually receives this course of treatment.

> Note: This pick list does not

show all the Institutes. User must type in a search criterion and then click on the ellipsis perform the search and

display the resulting

matched Institutes. Ex:

type %NCI% to list all the Institutes that

include the upper characters

'NCI' somewhere in

the Institute code.

Note: Optional for non-CTEP sponsored studies.

Use pick list.

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
CINI01	Start Date of Course cannot be in the future.	Change the Start Date of Course to a date no later than the current date.
CINI03	Course start dates must be unique and in order.	Ensure that no course start dates are repeated and that they appear in the correct chronological order (from the oldest to the more recent).

CINI04 If course initiation number is greater than 1, then prior course should exist first.	Ensure the previous course was entered
---	--

Derivations

Code	Field Name	Description
CINI1002	Course #	Course number derived by the system based on the dates the courses started.

ECG


Contents


- Purpose
- ECG eCRF
- Validations
- Derivations

Purpose

Record the patient's ECG.

ECG eCRF





Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number the ECGs are related to based on their date and time.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course the cardiac ejection fraction results are related to based on their date and time.	5 digits
Date of Exam ^(m)	Enter the date the ECG was performed.	DD-MMM-YYYY
Time	Enter the time the ECG was performed.	HH(24):MM

QRSD Interval	Enter the QRS duration (QRSD) interval in milliseconds.	8 digits.
QT Interval	Enter the QT interval in milliseconds.	3 digits.
QTC Interval	Enter the QTC interval in milliseconds.	3 digits.
PR Interval	Enter the PR interval in milliseconds.	3 digits.
ECG Impression ^(m)	Select one of the following summary finding: A - Abnormal B - Borderline N - Normal	Use pick list.
Rate ^(m)	Enter the patient's pulse rate.	3 digits.
Rhythm ^(m)	Select one of the following rhythm finding: A - Abnormal N - Normal	Use pick list.
Arrhythmia Type	Select the patient's arrhythmia type.	Use pick list.
P Wave	Select one of the following P Wave finding: A-Abnormal N-Normal	Use pick list.
QRS Complex	Select one of the following QRS Complex finding: A-Abnormal N-Normal	Use pick list.
ST Segment	Select one of the following ST Segment finding: A-Abnormal N-Normal	Use pick list.
Comments	Enter comments applicable to the ECG.	200 characters

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
ECG01	Date of Exam is in the future.	Enter a date that is equal to or prior to the current date.

Derivations

Code	Field Name	Description
ECG1001	Course #	Course number is derived based on the course initiation start dates and the Evaluation Date.
ECG1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the Evaluation Date.

Eligibility Checklist

Contents

- Purpose
- Eligibility Checklist eCRF
- <u>Validations</u>
- Eligibility Checklist eCRF
- Validations

Purpose

Record the patient's status for each item of the eligibility checklist.

Each activated protocol has a customized eligibility checklist.

Eligibility Checklist eCRF

Inclusion Criteria tab (sample criteria)





Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the form was completed (i.e. the date information was gathered).	DD-MMM-YYYY

Checklist Number

Checklists are numbered sequentially based on NCI approval of amendments that change the eligibility criteria. The eligibility checklist from the original protocol must number 0. Each time the eligibility criteria for a protocol are amended, the checklist number is incremented. (The checklist number may not be the same as the amendment number, since some amendments do not affect the criteria.) The appropriate checklist number is provided by CTMS along with a new customized CRF each time a revised protocol-specific Eligibility Checklist is formulated.

2 digits

Note: This field cannot be modified by the user.

Effective Date

Date of approval of the eligibility criteria by NCI. For the original protocol, the effective date is the date of NCI approval of the study. For revised eligibility criteria, the effective date is the date of NCI approval of the relevant amendment. This date is updated by CTMS at the time the protocol specific checklist is completed or amended by CTMS.

Note: This field cannot be modified by the user.

DD-MMM-YYYY

Waiver Number	The waiver number when the patient is not formally eligible, but is admitted to the study. A reason must be entered in "Eligibility Waiver Reason" field of the Exclusion Criteria tab.	12 characters
	Note: Not applicable for NCI/DCTD/CTE P sponsored studies.	
Criterion Response ^(m)	Select the patient's status relative to the eligibility inclusion criterion. Y - Yes N - No X - Not Applicable	Use pick list.
	Note: Do not leave this field empty. Select one of the above responses.	
Sequence	The inclusion criterion sequence number. Note: This field cannot be modified by the user.	2 digits


Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.


Validations

Code	Description	Resolutions
EC01	Waiver Number provided but no Eligibility Waiver Reason has been provided and vice-versa.	An Eligibility Waiver Reason must accompany a Waiver Number.

Eligibility Checklist eCRF

Exclusion Criteria tab (sample)





Field Name	Description / Instructions	Format
Criterion Response ^(m)	Select the patient's status relative to the eligibility exclusion criterion. Y - Yes N - No X - Not Applicable Note: Do not	Use pick list.
	leave this field empty. Select one of the above responses.	
Sequence	The exclusion criterion sequence number. Note: This field cannot be modified by the user.	2 digits
In the opinion of the investigator, is the patient eligible? ^(m)	Select the investigator's decision. Y - Yes N - No X - Not Applicable	Use pick list.

Eligibility Waiver Reason	Patients who are not eligible as per protocol criteria should not be entered on study. If after an appropriate review of the patient's status it is determined that the patient violates one or more of the eligibility criteria, or if no information is available for some of the criteria, the Principal Investigator should state concisely and clearly why the patient has been admitted to the study.	
	Note: since CTEP does not issue or approve any waivers, providing this explanation will not make the patient eligible for the study.	

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
EC01	Waiver Number provided but no Eligibility Waiver Reason has been provided and vice-versa.	An Eligibility Waiver Reason must accompany a Waiver Number.

Enrollment

Contents

- Purpose
- Enrollment eCRF
- Validations
- Derivations

Purpose

Record the patient's enrollment information at the time of study entry.

For studies that require de-identified patient data, fields such as Date of Birth (year only is acceptable), Patient Initials, Date from which to Start Including Labs, Primary ID, Country Code, Postal Code, Method of Payment will not be used.

Enrollment eCRF



Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the patient's registration date.	DD-MMM-YYYY
Gender^(m)^	Select the patient's gender: • FEMALE • MALE • UNKNOWN • UNSPECIFIED	Use pick list.
Date of Birth^(m)^	Enter the patient's date of birth.	DD-MMM-YYYY

Age at Entry^(d)^	Age is derived from the patient's birth date at the enrollment and it remains the same throughout the study.	5 digits and 2 decimal
	children less than 5, a fractional age (rounding to one decimal place is sufficient) will be derived to indicate the number of months since the last birthday. (For example, a child with a birth date of January 1 having passed his fourth birthday and entering the study on July 1 would have his age recorded as 4.5 years.)	
Patient Initials^(m)^	Enter the patient's initials. Usually 3 characters – first, middle and last name initials.	4 characters

Race^(m)^

There are five race fields. Use each field's pick list to select a race. The following races are available in the pick list:

- White: a person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
- Black or African American: a person having origins in any of the black racial groups of Africa.
- Asian: a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent (including the Philippine Islands).
- American Indian or Alaska Native: a person having origins in any of the original peoples of North, South, and Central America and who maintains tribal affiliation or community attachment.
- Native Hawaiian or other Pacific Islander: a person having origins in any of the original peoples of Hawaii, or other Pacific Islands.
- Not Reported: patient refused or data not available.
- <u>Unknown</u>: patient is unsure of their race(s)

 Note: If "Not Reported" or "Unknown" is selected, then no other race can be selected. Use pick list.

Ethnicity^(m)^	Select one of the following OMB ethnicity categories: • <u>Hispanic or Latino</u> : a person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. • <u>Non-Hispanic or Latino</u> : a person not meeting the definition for Hispanic or Latino. • <u>Unknown</u> : a person of unknown ethnicity. • <u>Not Reported</u> : Not provided or available	Use pick list.
Registering Institution^(m) ^(c)	Enter the unique CTEP Institute Code where the patient was originally registered on study (e.g., institution where the patient signed the informed consent form). Note: This field is not mandatory for non-CTEP studies.	Use pick list.
Primary ID^(m)^	Enter the patient's medical record number for the selected Institution. The Clinical Center's medical record numbers have the following format: 99-99-99-9 For non clinical center patients, enter the Unique Identification number provided by the Central Registration Office. This number is a combination of a site code and patient position code. These medical record numbers are used to load the patient's lab data.	12 characters

Patient Subgroup^(c)^	Select the appropriate unique code for identification of uniform groups of patients for separate analysis or treatment as defined in the Clinical Data System (CDS). Patient "Subgroup" codes are provided by CTEP to the investigator at the time of protocol approval, and are updated as required following approval of protocol amendments.	Use pick list.
Registering Group^(c)^	Enter the unique CTEP Group code (as listed on the CTEP Web site) from which the patient was originally registered on study. Note: This is required for Inter-Group trials only – otherwise leave blank.	Use pick list.
Country Code^(c)^	Required for non-US residents. For patients from outside the U.S., enter the foreign country code. Please use the International Standards Organization (ISO) Country codes which can found at CTEP Country codes list.	Use pick list.
Postal Code^(c)^	For U.S. residents, enter the patient's home 5 digit zip code. Do not enter the last 4 digits of the complete zip code to assure patient confidentiality. Also do not enter the dash "-".	10 characters

Method of Payment^(c)^	Select the patient's primary method of payment using the following codes: 1 - Private Insurance 2 - Medicare 3 - Medicare and Private Insurance 4 - Medicaid 5 - Medicaid and Medicare 6 - Military or Veterans Sponsored NOS 6A - Military (including CHAMPUS or TRICARE) 6B - Veterans Sponsored 7 - Self pay (no insurance) 8 - No means of payment (no insurance) 98 - Other 99 - Unknown	Use pick list.
Primary Disease Site^(m)^	Select the primary disease site of the malignancy from the pick list.	Use pick list.
Disease Term^(m)^	Select a disease term. Use the list of Disease Terms ("MedDRA") as listed on the CTEP Web site.	Use pick list.
Disease Stage at Entry	Select the stage of the disease at the time of study entry if appropriate. Otherwise, leave it blank.	Use pick list.
Disease T Stage	Select the stage of disease based on the primary tumor.	Use pick list.
Disease N Stage	Select the stage of disease based on the nodes present.	Use pick list.
Disease M Stage	Select the stage of disease based on the metastases present.	Use pick list.
Histology / Cytopathology	State briefly the type of histology or cytopathology found at the time of original diagnosis. Do not state broad categories (e.g., "lymphoma", but rather state "Non-Hodgkin's lymphoma").	50 characters (40 reported)

Date of Confirmation of Histology	Enter the date when the patient's disease status was confirmed, at the treating institution, prior to study entry (if required by the protocol).	DD-MMM-YYYY
Grade of Histology	Enter the grade of histology at study entry, if appropriate. Leave it blank otherwise. i Note: Grade of Histology is the Gleason Score for Prostate Patient.	10 characters(4 reported)
Date of Diagnosis	Enter the first date of original diagnosis (e.g., when a positive biopsy or surgical result was obtained). Do not give the start date of symptoms as the date of diagnosis.	DD-MMM-YYYY
Treatment Assignment Code^(m)^(c)	Select the appropriate code for the patient's treatment assignment as specified. For non-CTEP studies, "Treatment Assignment" codes are based on the treatment schedules described in the protocol. Please contact the Informatics team for advice on TAC formulation and modification. For CTEP sponsored studies, "Treatment Assignment" codes are provided by CTEP to the investigator, in the form of a coding letter, at the time of protocol approval, and are updated as required following approval of protocol amendments. Advice on TACs is available from the CTEP's Protocol and Information Office (pio@ctep.nci.nih.gov) (mailto:(pio@ctep.nci.nih.gov)).	Use pick list.
Date Informed Consent Signed^(m)^	Enter the date the patient signed the informed consent form.	DD-MMM-YYYY

Date of Informed Consent Version^(m)^	Enter the date of the informed consent version of the IRB-approved informed consent form that was signed by the patient at the time of study entry. This will be the date that is displayed on page one of the consent form in the section entitle: "Latest Amendment Approved:" or the date displayed on the "Latest IRB Review" when the amended date is N/A.	DD-MMM-YYYY
Date from which to Start Including Labs^(m)^	Enter the date indicating when lab results data should be start being loaded from the centralized lab. Usually prior to the patient's informed consent.	DD-MMM-YYYY

Code	Description	Resolutions
ENR01	Date Informed Consent Signed is before Date of Birth.	Change the Date Informed Consent Signed to be after the Date of Birth.
ENR02, ENR04, ENR05, ENR06, ENR17	Date of Birth, Date of Confirmation of Histology, Date of Diagnosis, Date Informed Consent Signed, Date of Informed Consent Version are in the future.	Enter a date that is prior or equals to today's date.
ENR07	All Races are unchecked.	Select at least one Race.
ENR09, ENR10, ENR11, ENR12	Birth Date is after the Date from which to include labs, Date of Confirmation of Histology, Date of Diagnosis, Date Informed Consent Signed, Informed Consent Version Date.	Correct the Date of Birth or the other date fields.
ENR14	Date of Diagnosis is after Date of Histology Confirmation (if provided).	Correct Diagnosis Date or Date of Histology Confirmation.

ENR15, ENR16	Cannot select another Race when "Unknown" or "Not Reported" Race is selected.	Unselect the other Races and select only "Unknown" or "Not Reported". Or unselect both "Unknown" or "Not Reported" and select other Races.
ENR18	Registering Institution not found on the patient's Medical Record Numbers case report form.	Please review the Institutions on both case report forms.
ENR20	Enrollment only has part of the TNM Disease Stage information available	If one of the TNM fields is answered, the rest should be available.

Derivations

Code	Field Name	Description
DM1001	Age	The age is derived from the patient's Informed consent signed date and the date of birth. Note: Age is expressed in decimals to accommodate patients under the age of 5.

Extent of Disease (Neuro Oncology Branch)

Contents


- Purpose
- Extent of Disease eCRF
- <u>Validations</u>
- Derivations

Purpose

This is a Case Report Form specific to the Neuro Oncology Branch. It is used to record Brain Tumors.

Record all sites of disease, even if they will not be followed for response.

Extent of Disease eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Lesion # field.	DD-MMM-YYYY
Day in Course (d)	Day in Course based on the Course Start and Stop Dates and the Date of Scan	99999
Side		Use pick list.
CNS Site Location		Use pick list.
Enhancing Lesion		Use pick list.
Date of Scan		DD-MMM-YYYY
Imaging Modality		Use pick list.

Measurable Lesion	Enter "M", for measurable, and "N" for non-measurable, as defined in the protocol.	Use pick list.
Measurement - Diameter 1		9999.99
Measurement - Diameter 2		9999.99
Measurement - Product		999999.99
% Change from Baseline or Best Response		999.1
Evaluable Lesion		Use pick list.
Evaluation Enhanced (GAD) Code		Use pick list.
Evaluation Flair Code		Use pick list.
Radiographic Response Assessment		Use pick list.
Comments		200 characters

Validations

CodeDescriptionResolutionsEXT ???

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Derivations

Code	Field Name	Description
EXT2001	Course #	Course number is derived based on the course initiation start dates and the extent of disease date of scan.
EXT2001	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the extent of disease date of scan.

Extent of Disease

Contents

- Purpose
- Extent of Disease eCRF Lesions Identification
- Validations
- Extent of Disease eCRF Lesions Measurements
- Validations
- Derivations

Purpose

Record all sites of disease, even if they will not be followed for response.

Extent of Disease eCRF - Lesions Identification



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Lesion # field.	DD-MMM-YYYY

Lesion # ^(m)	Select a unique number for each lesion. Once a lesion number is designated for a specific lesion, that number may not change or be used to denote a different lesion. Note: This lesion number must	Use pick list.
	appear at least once on the bottom repeating group.	
Anatomic Site^(m)^	Select the anatomic position where the lesion is located, i.e. Lung, Skull, etc.	Use pick list.
Description of Location^(m)^	Select a brief description of the lesion location.	Use pick list.
Description of Lesion	If applicable, enter a brief description of each lesion, e.g. cystic, well-defined, encapsulated, necrotic appearing center.	32 characters
Previously Irradiated^(m)^	If the site or lesion has previously been irradiated, enter "Y" for Yes, otherwise enter "N" for No.	Use pick list.
Measurable / Non-Measurable^(m)^	Enter "M", for measurable, and "N" for non-measurable, as defined in the protocol.	Use pick list.

Target / Non-Target (m)

Enter "Target" for target lesions that will be assessed for response (e.g. using the RECIST response criteria). Enter "NonTarget" for non target lesions.

Note: Only applicable for studies that use RECIST criteria. It applies to the first time the lesion is detected. It should not be changed based on the subsequent evaluations. For CTMS studies, 'Target' will be submitted as 'Y', 'NonTarget' will be submitted as ίΝ'.

Use pick list.


Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Validations

Code	Description	Resolutions
EXT01	Lesion Number appears more than once on the description section.	Extent of Disease Lesion Number should be unique in the description section (top repeating group).

Extent of Disease eCRF - Lesions Measurements





Field Name	Description / Instructions	Format
Lesion # ^(m)	Select a lesion number from the pick list. i Note: This lesion number must appear in the description section (top repeating group).	Use pick list.
Course # ^(d)	Indicates the course number that this lesion evaluation was done in as derived from the course initiation start date.	5 digits
Day in Course^(d)^	Indicates the day since the beginning of course that this lesion evaluation was done as derived from the course initiation start date.	5 digits
Evaluation Date^(m)^	Enter the date of the evaluation (i.e.: date of CT scan). Do not enter the date of the report or when the results were received.	DD-MMM-YYYY

How Measured^(m)^	Select how the lesion measurement was determined. The same method should be used to measure a specific lesion throughout the study. For example, if the measurements were determined by a chest x-ray, enter CXR.	Use pick list.
First Longest Measurement	Enter the longest lesion measurement in centimeters. Note: for studies that use RECIST criteria, it should always measure the longest diameter of the lesion even if the actual axis is different from the one used to measure the lesion initially.	6 digits and 2 decimals
Second Longest Measurement	Enter the second longest lesion measurement in centimeters. i Note: not applicable for studies that use RECIST criteria.	6 digits and 2 decimals
Third Longest Measurement	Enter the third longest lesion measurement in centimeters. Note: not applicable for studies that use RECIST criteria.	6 digits and 2 decimals
Product	Enter the tumor product which is the multiplication of the First and Second Longest Measurements.	8 digits and 2 decimals

Total Tumor Volume	Enter the total tumor volume which is the multiplication of all three measurements. 8 digits and 2 decimals
Evaluation # ^(m)	Number each evaluation sequentially for each lesion. Use 0 for the baseline evaluation, 1 for the first evaluation, 2 for the second evaluation, etc. Note: this is the number of the set of scans done after the baseline. For example, if a new lesion was found on the third set of scans that occurred at the end of the course 4, the evaluation number should be 3.
Evaluation Code	Select the status of non-measurable lesions at the time of each evaluation. B - Baseline (use for the initial lesion evaluation that was when the treatment started.) D - Decreasing I - Increasing N - New (use for lesions that appear after treatment has started.) R - Resolved S - Stable X - Not Examined V - Not Evaluable



EXT02	Lesion Number in the measurement section does not have a corresponding number in the description section (Lesion Identification Page).	Verify that lesion number in the measurement section is recorded in the description section(Lesion Identification Page).
EXT03	Evaluation Number of a measurable lesion is "0" and Evaluation Code is not "B - Baseline" or "N-New". And vice-versa.	If Evaluation Number of a measurable lesion is "0", Evaluation Code should be "B - Baseline" or "N-New".
EXT12	Lesion is marked as "Measurable" and longest measurement do not exist.	Enter the lesion's longest measurement.
EXT05	Date of Evaluation is in the future.	Enter a date that is equal to or prior to the current date.
EXT09	Lesion is marked as "Non-Measurable" and Evaluation Code was not provided.	Lesion is marked as "Non-Measurable" should have an Evaluation Code.
EXT13	The lesion has an Evaluation Code of "B - Baseline" and the Evaluation Date is not prior to Start Date of the first course.	Correct the lesion's Evaluation Date or the Evaluation Code.
EXT14	Evaluation Date for New lesion is prior to the Start Date of first course.	Enter a date that is equal or after the first course Start Date.
EXT15	Evaluation number for New lesion (with Evaluation Code 'N-New') is 0.	Enter a correct sequential number.
EXT16	New lesion (with Evaluation Code 'N-New') does not have the lowest evaluation number for the corresponding lesion.	Enter a correct sequential number.

Derivations

Code	Field Name	Description
EXT1001	Course #	Course number is derived based on the course initiation start dates and the extent of disease evaluation date.

EXT1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the extent of disease evaluation date.
---------	---------------	--

Follow up

Contents


- Purpose
- Follow-up eCRF
- <u>Validations</u>

Purpose

Record each follow-up contact as identified in the protocol.

There is no need to complete this Case Report Form if the patient died during the treatment portion of the study. Survival CRF still needs to be completed.

Follow-up eCRF





Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Last Contact field.	DD-MMM-YYYY
Date of Last Contact ^(m)	Enter the date the patient was last contacted. If the patient is being considered lost to follow-up (i.e.: unsuccessful contact with the patient / family / health care provider), please indicate the date that no further follow-up will be attempted.	DD-MMM-YYYY

Type of Contact ^(m)	Select how the information was obtained: 1. Telephone contact with patient 2. Telephone contact with patient's family 3. Telephone contact with patient's local physician 4. Social Security Death Index (SSDI) 5. Clinic Appointment 6. Mail contact with the patient 7. E-Mail contact with the patient	Use pick list.
Received Treatment Since Last Contact? ^(m)	If the patient has received further treatment since the last contact, select Y - Yes N - No Note: When answering 'Yes' and the patient has died during the follow-up period, only the Date of Death, entered on the Survival case report form, is sent to CTMS. Cause of Death and Autopsy information are not sent.	Use pick list.
Patient Status ^(m)	Select one of the options below that indicates the patient's last known status. If the patient has died, enter the date in the Date of Death field. If status is unknown, enter some explanation on the field labeled "Unknown (explain)". 1. Alive with disease 2. Alive with no evidence of disease 3. Alive disease status unknown 4. Unknown (Explain) 5. Died	Use pick list.

Explain 'Unknown' Patient Status	If Patient Status is unknown, enter some explanation here. Include what attempts were made and how many attempts where made in order to obtain the patient's status (i.e.: no response to 5 messages left).	24 characters
----------------------------------	---	---------------

Code	Description	Resolutions
FLW05	Date of Last Contact is in the future.	Enter a date earlier than, or equals to, the current date.
FLW06	Date of Last Contact is not within the Date Off Treatment and Date Off Study.	Date of Last Contact must fall between the Date Off Treatment and Date Off Study.
FLW07	Duplicate Date of Last Contact.	Date of Last Contact must be unique.
FLW08	Patient Status is "Unknown" and explanation is missing.	Patient Status "Unknown" requires an explanation.
FLW09	Explain "Unknown" Patient Status was provided, but Patient Status is not "Unknown".	Patient Status "Unknown" is required if an explanation for "Unknown" Patient Status is provided.

Infection Episode


Contents

- Purpose
- Infection Episode eCRF
- Validations
- Derivations

Purpose

Record information summarizing episodes of infection associated with treatment. This case report form is only to be used when the primary endpoint for the study is to assessing infectious episodes, either types and or number of events. Additional comments may, if needed, be reported in the comment tab.

Infection Episode eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Onset field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number that this infection episode occurred in as derived from the course initiation start date.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course that this infection episode occurred in as derived from the course initiation start date.	5 digits

Date of Onset ^(m)	Enter the date the infection episode began.	DD-MMM-YYYY
Date Resolved	Enter the date the infection episode resolved.	DD-MMM-YYYY
Infection Type ^(m)	Select the infection type. For example: pneumonia, UTI, URI, etc.	Use pick list.
Primary Site ^(m)	Select the primary site of the infection.	Use pick list.
Infectious Agent	Select the actual infectious agent, determined from culture or other appropriate test.	Use pick list.
Treatment	Select the treatment (or lack of) given for this infection. This treatment should also be recorded on the Concomitant Measures / Medications case report form.	Use pick list.
Procedure	Select the procedure (or lack of) done for this infection. This procedure should also be recorded on the Procedures case report form.	Use pick list.
Outcome	Select the outcome of this episode. 1. Recovered 4. Died	Use pick list.

Code	Description	Resolutions
IFE01	Date of Onset of the Infection Episode is greater than the Resolve Date.	Date of Onset must be prior than Resolve Date
IFE02, IFE03	Date of Onset and/or Date Resolved are/is in the future.	Enter a date that is equal to or prior to the current date.
IFE05	Date of Onset, Infection Type, Treatment and Procedure appear more than once.	An Infection Type, Treatment and Procedure can only be entered once for a particular Date of Onset.

IFE06	Resolved Date provided, but Outcome is missing.	Outcome must be entered if Date Resolved is provided.
IFE07	Date Resolved is missing, but Outcome was provided.	Date Resolved must be entered if Outcome is provided.
IFE08	A Concomitant Measure / Medication with an Agent matching the Infection Episode Treatment with the same Start Date and Date of Onset was not found.	An Infection Episode Treatment must have an entry in the Concomitant Measure / Medication case report form with the Start Date the same as the Date of Onset.
IFE09	A Concomitant Measure / Medication with a Procedure matching the Infection Episode Procedure with the same Start Date and Date of Onset was not found.	An Infection Episode Procedure must have an entry in the Concomitant Measure / Medication case report form with the Start Date the same as the Date of Onset.

Derivations

Code	Field Name	Description
IFE1001	Course #	Course number is derived based on the course initiation start dates and the infection episode Date of Onset.
IFE1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the infection episode Date of Onset.

Labs

Contents

- Purpose
- Labs eCRF
- Validations
- Derivations

Purpose

Record the patient's lab results.

Patients on NCI/CCR's intramural studies who have their labs drawn at the Clinical Center will use the Lab Load Interface (LLI) tool to select which labs results to electronically transfer into C3D. The selected results are then loaded onto the appropriate Lab Panel CRFs overnight. Instructions on how to use the LLI tool are in appendix IV.

2007 and earlier C3D Studies, in general, do not use the LLI tool and labs done in the Clinical Center are automatically loaded directly in C3D.

It takes at least 48 to 72 hours for Clinical Center Labs to become available to C3D.

Outside labs need to be manually entered in C3D. Refer to the 'Inserting Unplanned Visits' section of the General Instructions of this manual.


It is common to have several forms of the same kind of lab for a patient. Click on the C3D RDC worksheet column header labeled "Show unplanned visit" to see all these extra lab results.

The following table lists the standard lab CRFs and appendix III the tests in each of them. The C3D Study will have only the appropriate lab CRFs as specified by the Protocol.

Blood Chemistries	• CSF	Respiratory Functions	Blood Gases
Hematology	Serology	Bone Marrow	Lymphocyte Phenotype
Serum Electro	Chimerism Lab	Other Serum Chemistries	Urinalysis
Coagulation	Other Urinary Results	Urine Immune Electro	• HLA

Labs eCRF





Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the lab sample was collected.	DD-MMM-YYYY
Time ^(m)	Enter the time the lab sample was collected. Enter midnight as 24:00 since 00:00 is used when time is not known.	HH(24):MM
Lab	Select the source of the lab results. DIm - Lab results automatically loaded from another system. DIm\$Diabetic - Not in use. Do not use. Outside - Outside lab results entered manually. Respfunc - Not in use. Do not use.	Use pick list.
Course # ^(d)	Indicates the course number this lab is related to.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course this lab is related to.	5 digits
Lab Test ^(d)	Pre-defined name of the lab test. Each lab panel has a different set of tests which are listed at the appendix III.	20 characters

Value	Enter the lab test result value as reported.	20 characters.
UOM	Select the appropriate lab test value unit of measurement.	Use pick list.
Normal Range	For labs loaded from the MIS/CRIS system, the range is automatically populated. For labs obtained outside the NCI Clinical Center, enter the appropriate normal range.	30 characters
Range Indicator ^(d)	Indicates how the lab result value compares to the lab test normal range. NORMAL - Falls within the normal range. HIGH - Above the normal range. LOW - Below the normal range. NONNUM - Not a valid number (e.g. "No Data"). NORANG - No normal values are provided.	12 characters
Grade ^(d)	Derived from the lab test result value and the lab test ranges from the version of the NCI Common Terminology Criteria for Adverse Events (CTCAE) specified by the Protocol. Note: The age and gender are also factors in some cases.	13 characters
Value (Numeric) ^(d)	Derived from lab test result value.	12 characters
Talao (Hamono)		
Value in Preferred UOM ^(d)	Derived the lab test result value in the preferred unit of measurement which is pre-defined by the institute.	12 characters
Preferred UOM ^(d)	The preferred unit of measurement for the specified lab test.	20 characters

Validations

Code	Description	Resolutions
LB01	Lab test has grade higher than zero or than the most recent baseline lab test grade but no relevant Adverse Event exists.	Correct the lab grade or make sure a relevant Adverse Event exists.
LB03	Two labs exist for the same date and time.	Review both labs and delete/correct one of them.

Derivations

Code	Field Name	Description
LBAL1003	Course #	Course number is derived from the course initiation start date and the lab date (visit date).
LBAL1004	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the lab date (visit date).
LBAL1001	Range Indicator	Derived based on the lab value result and normal high/low range.
LBAL1002	Grade	Derived from the lab test result value, unit of measurement and the lab test normal range.

Medical Record Numbers

Contents

- Purpose
- Validations

Purpose

Record the patient's medical record number(s).

This CRF is not used for studies that require patient data de-identification.



Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the patient's registration date.	DD-MMM-YYYY
Institution ^(m)	Select one of the CTEP Registering Institutions.	Use pick list.
Patient Medical Record Number ^(m)	Enter the patient's medical record number for the selected Institution. The Clinical Center's medical record numbers have the following format: 99-99-99-9 For NCINAV and other institutions, enter the medical record number following the institution's format. These medical record numbers are used to load the patient's lab data.	12 characters

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
MRN01	An NCI Institution has been selected (except for NCINAV) and Patient Medical Record Number does not have 10 characters.	For NCI Institutions (except NCINAV) the Patient Medical Record Number must be entered in the following format: 99-99-99-9
MRN02	An NCI Institution has been selected (except for NCINAV) and Patient Medical Record Number checksum is invalid.	Enter the correct Patient Medical Record Number.
MRN03	Patient Medical Record Number is the same for different Institutions.	Verify and correct the Institution and/or Patient Medical Record Number.

Off Study

Contents

- Purpose
- Off Study eCRF
- Validations

Purpose

Record information concerning the patient's off study date and reason. Complete this form after the patient has been taken off study.

For studies without a protocol specified follow-up period, this form is completed when the patient is taken off treatment. The off study date, reason and explanation must be the same as the off treatment case report form date off treatment, reason and explanation respectively.

For studies with a protocol specified follow-up period, this form is completed when all follow-up time points and data have been collected as specified in the protocol or if the patient dies within the follow-up period or if follow-up period ends for any other reason. If the off treatment reason prevents the follow-up period from occurring, then the off study date, reason and explanation must be the same.

No further data will be collected once this form is completed.

Off Study eCRF





Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the form is being completed.	DD-MMM-YYYY

Date Off Study ^(m)	For protocols with a specific follow-up period, enter the date that corresponds to the date when all protocol specific follow-up has been completed. For protocols without a protocol specific follow-up, enter the date that the patient came off treatment, i.e. courses have been completed (including the normal observation period) or discontinued and no further treatment courses are planned. This date must be the same as the Date Off Treatment entered on the Off Treatment case report form. The date off study will correspond to a progress note in the medical record stating that the patient has been taken off study. Note: For CTMS studies, this is the 'Date off follow-up period'.	DD-MMM-YYYY
Reason Off Study ^(m)		Use pick list.

For protocols without a protocol specific follow-up, use the same 'Reason Off Treatment' entered on the Off Treatment case report form.

For protocols with a follow-up period, the following off study reasons are also available.

Y - Completed treatment period but refused the Protocol-Specified Follow-up. Date Off Treatment and Date Off Study must be the same.

H - Follow-up Period Completed:

The patient completed all protocol specified follow-up evaluations.

L - Lost to Further Follow-up:

Follow-up information could not be obtained because contact with the patient was lost. Every effort to locate patient needs to be considering including: contact with family members, referring physicians, sending certificate letter, checking SSDI.

W - Refused Further Follow-up:

The patient has refused to have any further follow-up evaluations.

M - Death during Follow-up

Period: The patient died during the follow-up phase of the protocol. The Date Off Study must coincide with the date of death (located on the Survival case report form).

J - Disease Progression during Follow-up Period: The patient was taken off study for disease progression during the follow-up period. A Date of Progression must be entered.



Note: For CTMS protocols, the actual Reason Off Study sent is 'K' and the explanation text is - 'Disease Progression during Follow-up Phase'.

	K - Other Reasons: Other reasons may be given for taking the patient off study. Enter an explanation in the "Explain 'Other' Reason" field.	
Explain 'Other' Reason	Enter an explanation for selecting "Other" for a Reason Off Study. For protocols without a protocol specific follow-up, repeat the same explanation entered on the Off Treatment case report form.	24 characters
Date of Disease Progression	If disease progression is selected as the reason the patient came off study, enter the date the disease assessment (i.e.: CT scan) was performed. i Note: This date is not sent to Theradex since only Disease Progression during treatment is to be reported.	DD-MMM-YYYY

Code	Description	Resolutions
OSS13, OSS14	Date Off Study and/or Date of Progression cannot be a date in the future.	Enter a date earlier than, or equals to, the current date.
OSS01	Reason Off Study is 'Death' and Date Off Study is not equal to Date of Death on Survival form.	If patient died during the protocol follow-up period or during treatment, Date Off Study must coincide with Date of Death.
OSS03	Reason Off Study is Protocol Violation and a comment with the off study date does not exist.	If patient treatment was terminated due to Protocol Violation, then reason must be stated in the Comments tab of this form.

OSS18	Explain 'Other' Reason provided, but Reason Off Study is not 'U', 'O' or 'K'.	Only 'Other' reasons can have an explanation.
OSS19	Reason Off Study is 'U', 'O' or 'K' and Explain 'Other' Reason not provided.	'Other' reasons must have an explanation in the Explain 'Other' Reason field.
OSS20	Date Off Study and Date Off Treatment are the same, but Reason Off Study is not "Y - Refused participation in follow-up", or "K - Other" or the same as the Reason Off Treatment.	When the Date Off Treatment and Off Study are the same, the Reason Off Study must be the same as the Off Treatment Reason or "Y" or "K".
OSS21	Date of Disease Progression cannot be after Date Off Study	Enter a Date of Disease Progression that is earlier than or equal to the Date Off Study.
OSS22	Disease Progression selected as Reason Off Study and Date of Disease Progression is missing.	A Disease Progression for Reason Off Study requires a Date of Disease Progression.
OSS23	Date of Disease Progression provided and Reason Off Study is not Disease Progression.	Date of Disease Progression must be accompanied by a Reason Off Study of 'Disease Progression'.
OSS24	Off Treatment Date of Disease Progression is blank, Off Study Date of Disease Progression is not blank and it doesn't fall between the Date Off Treatment and Date Off Study.	Date of Disease Progression must be between Date Off Treatment and Date Off Study when progression did not occur during treatment – it occurred during the follow-up period.
OSS25	Reason Off Treatment is Disease Progression, Date Off Treatment and Date Off Study are the same and Date of Disease Progression is not the same as the one in the Off Treatment form.	When Disease Progression is the Reason for Off Treatment and Off Study, then Date of Disease Progression must be the same on both forms.
OSS27	Off Study Date is provided but the Off Treatment Date is absent.	Enter the Off Treatment Date on Off Treatment form.

Off Treatment

Contents

- Purpose
- Off Treatment eCRF
- Validations
- Derivations

Purpose

Record information concerning the patient's off treatment date, reason and best response to treatment.

For studies without a protocol specified follow-up period, also complete the Off Study case report form entering the same Date, Reason and, if applicable, the Reason Explanation and Date of Disease Progression. Also complete the Off Study form with the same information when the Reason Off Treatment prevents the follow-up period from occurring.

Off Treatment eCRF





Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the date the form is being completed.	DD-MMM-YYYY
Date Off Treatment^(m)^	Enter the date when all courses have been completed (including the normal observation period) or discontinued and no further treatment courses are planned. This date will correspond to the clinic visit that would have served as the pre-course visit had the patient continued on therapy. This is the date the patient has been officially taken off treatment.	DD-MMM-YYYY
Reason Off Treatment^(m)^		Use pick list.

Select an off treatment reason from one of the following reason groups: 1) If the patient's participation has been completed as per protocol, and the protocol does not specify a follow-up observation period, select:

C - Study Completed



 Note: Option 'C' is only available for studies without a follow-up period.

- 2) For patients who were evaluated for entry to the protocol and signed an informed consent form, but were not treated (never received any drugs or therapies per the protocol), select one of the following:
- X Patient Declined to Participate (before treatment started.)
- **B** Disease Progression before Treatment.
- **Z No Treatment, per protocol.**
- U Not Treated Other Reasons, explain - Enter an explanation in the Reason Other field
- 3) When the patient's participation terminated during treatment period, select one of the following:
- P Disease Progression On Study: The patient was taken off treatment for disease progression. This must be reflected by an increase in the non-measurable or measurable disease state. (See Course Assessment and Extent of Disease Forms). This can be

A Date of Progression must be entered.

manifested as clinical deterioration.

- **D Death During Treatment:** The patient has died during the treatment phase. The cause of death should be listed on the Survival case report form and, if applicable, on the Adverse Events case report form as well.
- T Adverse Events / Side Effects: The patient experienced any toxicity

that was considered related to the study medication, which prohibited further protocol treatment. Patients discontinued due to toxicity are evaluable provided the observation period has been completed per protocol. The toxicity must be listed on the Adverse Events form.

S - Complicating Disease / Intercurrent Illness: Patient was taken off treatment due to complicating disease not related to malignancy. This should be included in the Adverse Event form by an event not considered to be related to therapy.

G - Cytogenetic Resistance.

A - Switched to Alternative

Treatment: The patient was taken off treatment due to a decision to pursue alternative therapy (such as palliative radiation).

R - Refused Further Treatment: If at any time the patient refused further treatment.

I - Late Determination of Ineligibility: Patient was taken off treatment following treatment because follow-up tests indicate that patient was not eligible for the study.

V - Protocol Violation: If a major protocol violation has occurred, the reason must be stated in the Comments part of this case report form.

2 - Patient Noncompliance: If the patient did not comply with the study plan.



1 Note: For CTMS protocols, the actual Reason sent is 'O' and the explanation text is - 'Patient Noncompliance'.

- N PI Discretion: If PI made the decision. For CTMS protocols, the actual Reason sent is 'O' and the explanation text is - PI Discretion'.
- O Other: Other reasons may be given for taking the patient off treatment, although they may not be included in the protocol stipulated rules. The patient's evaluability will subsequently be determined. Enter an explanation in the Reason 'Other' field.
- 4) When the patient completes protocol-specified treatment period, select the following:

Q - Treatment Period Completed



Note: Option 'Q' is only available for studies with a follow-up period.

Explain 'Other' Reason Off Treatment

Enter an explanation for selecting "Other" for a Reason Off Treatment. 50 characters

Patient Began Protocol Specified Follow-up^(m)^	Indicate whether or not the patient began the protocol-specified follow-up period. Y - Yes N - No Note: This field is only available for protocols with a specified follow-up period.	Use pick list.
Date of Last Medication Administration (d)	Indicates date the last medication was administered.	DD-MMM-YYYY
Best Response to Treatment^(m)^	Select the best overall response to treatment while on protocol. CR - Complete response MR - Less than partial response NA - Not assessed NE - Not evaluable NP - Not applicable per protocol PD - Progressive disease PR - Partial response SD - Stable disease TE - Too early to access, per protocol CRU - Complete Response Unconfirmed NON-CR/NON-PD - Non Complete Response and Non Progressive Disease DU - Disease Unchanged For protocols not using RECIST criteria in assessing response, the following might be applicable to use. Consult/follow protocol for definition and usage criteria. MX - Mixed Response RP - Response NR - No Response According to RECIST and WHO guidelines this would be the best response assessed from the start of treatment until disease progression. Ordinarily this would be the best of the responses reported on the	Use pick list.

course assessment CRFs. For example, do not enter "SD" if the patient was assessed only with progressive disease.

Please be sure to enter the best response, not necessarily the response on the last course. For example, if the patient was assessed with a PR followed by a PD, enter the "PR".

If response was not assessed at all during the protocol treatment, enter the best response as NA; similarly for NE and NP.

RECIST: Unless the protocol includes specific response evaluation criteria, the following RECIST and WHO guidelines should be observed:

Responses of PR and MR are assessed relative to the baseline at start of treatment, not to previous courses. They must be confirmed by repeat assessments.

Subsequent evaluations at which tumor sizes are substantially unchanged should be assessed again as the same PR/MR.

A response of PD is relative to the best disease status (smallest tumor measurement) since treatment began. Thus a tumor re-growth after

	a PR would be assessed as PD not an MR. A PR or MR cannot follow a CR.	
Date of Best Response	Enter the date that a Best Response of Treatment response of CR, PR, or MR was first observed, or that an SD response began. This date must be consistent with the date entered on the Course Assessment case report form(s) and with evaluations on the Extent of Disease Form.	DD-MMM-YYYY
Date of Disease Progression	Enter the date that progression (or relapse) was first observed (i.e.: date of scan). This date is required if the Reason for Off Treatment is for Disease Progression. This date must be consistent with the date of progression entered on the Course Assessment form(s) and with evaluations on the Extent of Disease Form. Progression is the worsening of disease following a period of stable disease or a response. Relapse is the reoccurrence of disease in a patient with no evaluable disease at enrollment (e.g. on an adjuvant treatment study).	DD-MMM-YYYY

Code	Description	Resolutions
OTS05	Best Response to Treatment is not 'PD/NA/NE/NP/TE' and Date of Best Response is missing.	If anything other than 'PD/NA/NE/NP/TE' is checked for Best Response to Treatment, then Date of Best Response must be entered.
OTS07	Best Response to Treatment is 'Disease Progression' and Date of Progression is missing.	If 'Disease Progression' is checked for Best Response to Treatment, then Date of Progression must be entered.

OTS08	Date of Progression is not equal to the earliest Date of Progression reported on the Course Assessment forms.	Date of Progression must be consistent with Date of Progression on Course Assessment form(s).
OTS09	Best Response to Treatment is not the same as the best response reported on Course Assessment forms.	Best response should be validated against responses on Course Assessment form(s).
OTS10 OTS11 OTS12	Date Off Treatment, Date of Best Response and/or Date of Progression cannot be a date in the future.	Enter a date earlier than, or equals to, the current date.
OTS16	Reason Off Treatment is 'Death' and Date Off Treatment is not equal to Date of Death on Survival form.	If patient died during treatment, Date Off Treatment must the same as the Date of Death on the Survival form.
OTS17	Reason Off Treatment is 'Death' and Date Off Treatment is not equal to Date of Study on Off Study form.	If patient died during treatment, Date Off Treatment must the same as the Date Off Study on the Off Study form.
OTS18	Best Response date to Treatment is not same as the Best Response reported on Course Assessment forms	Best response date should be validated against response date on Course Assessment form.
OTS19	Reason Off Treatment is Protocol Violation and a comment with the date the patient ended treatment does not exist.	If patient discontinued due to Protocol Violation, then reason must be stated in the Comments tab of this form.
OTS20	Explain 'Other' Reason provided, but Reason Off Study is not 'U', 'O' or 'K'.	Only 'Other' reasons can have an explanation.
OTS21	Reason Off Study is 'U', 'O' or 'K' and Explain 'Other' Reason not provided.	'Other' reasons must have an explanation in the Explain 'Other' Reason field.
OTS26	For studies with protocol-specified follow-up period only: Answer to 'Patient Began Protocol-Specified Follow-up Period' is 'N - No' and there is no Off Study case report form or Off Study Reason is missing.	Please review the answer to 'Patient Began Protocol-Specified Follow-up Period' or enter an Off Study Reason.

OTS27	Other Reason in Off Treatment has more than 24 characters	Make Explanation for 'Other Reason' is less than 24 characters.
OTS28	Date of Disease Progression on Off Treatment is provided but there is no Date of Progression reported on the Course Assessment forms.	Make data consistent.

Derivations

Code	Field Name	Description
OTS1002	Date of Last Medication Administration	Indicates date the last medication was administered.

Pathology Report

Contents

- Purpose
- Pathology eCRF
- Pathology eCRF GROSS DESCRIPTION
- Pathology eCRF HISTOLOGY
- Pathology eCRF MICROSCOPIC DESCRIPTION

Purpose

Record Pathology information when required by the protocol.

Pathology eCRF



Field Name	Description / Instructions	Format
Surgical Pathology#	Entere the pathology Number	20 character
Surgery Date	Enter the date of the surgical procedure.	DD-MMM-YYYY
Pathology Resoults Date	Entere the pathology results date	DD-MMM-YYYY
Specify Other Procedure		100 characters
Body Site of Collection		Use Pick List


Pathology eCRF - GROSS DESCRIPTION



Field Name	Description / Instructions	Format
Pathology Sample Type	Slect the Pathology Sample Type	Use Picl List
Differentiation		Use Picl List
Condition of Margin		Use Picl List
Number of Lymph Nodes Sampled		Use Pick List
Number of Positive Lumph Nodes	Enter number of positive nodes	Nubmer (3)
Findings	Enter findings	24 characters
Greatest Dimension of Specimen (cm)		Number (6,2)
Second Greatest Dimension of Specimen (cm)		Number (6,2)
Stage of Disease	Enter Statge of Disease	Use Pick List
Disease T Stage	Select the stage of disease	Use Pick List
Disease N Stage	Select the stage of disease	Use Pick List
Disease M Stage	Select the stage of disease	Use Pick List
Histologic Grade	Enter the grade of histology	10 characters

Pathology eCRF - HISTOLOGY





Field Name	Description / Instructions	Format
Peritoneal Lavage Result		Use Pick List
Lymphatic Invasion Present		Use Pick List
Vascular Invasion Present		Use Pick List
Microcalcification Present		Use Pick List
Notable Benign Changes		Use Pick List
If Yes, Description (Specify)		200 characters

Pathology eCRF - MICROSCOPIC DESCRIPTION



Field Name	Description / Instructions	Format
Is this patient evalauable for immunostaining (IHC)	Yes No	Use Pick List
Tumor Marker		Use Pick List
Analyzed	Yes No	Use Pick List

Assay Date		DD-MMM-YYYY
Marker Test Method		Use Pick List
Intensity Score		Use Pick List
Cell Staining %		Number(3)
Mutation Detected	INDETERMINATE NO YES	Use Pick List
Result	NEGATIVE POSSITIVE UNKNOWN	Use Pick List
Biomarker Comments	Enter the comments	200 characters
Path Report Description	Enter desctioption of pathology report	200 characters

Pharmacokinetics


Contents

- Purpose
- Pharmacokinetics eCRF
- Validations
- Derivations

Purpose

Record detailed information about the collection of biological samples for analysis of the presence and quantity of the study agent and/or its metabolites. Since this form is intended to stand alone, some of the fields may duplicate items found in other case report forms.

Pharmacokinetics eCRF



Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the study agent administration was started.	DD-MMM-YYYY
Course Number ^(d)	Course number derived from the study agent start date and course initiation start dates.	5 digits
Day in Course ^(d)	Number of days since the start of the course. Derived from the study agent start date and course initiation start dates.	5 digits

Study Agent ^(m)	Enter the name of the study agent (investigational or commercial) which is the subject of the pharmacokinetic study. Note: Only one study agent is allowed per case report form. Separate forms should be used when more than one study agent is being studied.	Use pick list.
Start Date ^(m)	Enter the date the study agent administration was started.	DD-MMM-YYYY
Start Time ^(m)	Enter the time the study agent administration began.	HH(24):MM
Stop Date	Enter the date the study agent administration was stopped Note: This field will be used for infusional therapies only.	DD-MMM-YYYY
Stop Time	Enter the time the study agent administration was stopped. Note: This field will be used for infusional therapies only.	HH(24):MM

Specimen Sampled ^(m)	Select the body fluid that is being collected for the biological samples. A - Apheresis Cells B - Whole Blood C - Cerebrospinal E - Pericardial Effusion F - Abdominal Effusion M - Peripheral Blood Mononuclear Cells P - Plasma S - Serum T - Tumor Tissue R - Pleural Effusion V - Saliva i Note: Urine sample collection will be documented on the Urinary Excretion Case Report Form.	Use pick list.
Sample ID Number	If the specimen acquisition labeling process uses a bar code (or similar) system, enter the unique sample identification number for each of the planned interval time points samples.	10 digits
Planned Interval	Planned interval pre-determined per protocol.	80 characters
Sample Collected? ^(m)	Indicate whether or not the specimen is collected. YES - then the Sample ID (if applicable), Actual Start Date and Time should be entered NO UNKNOWN	Use pick list.
Planned Interval	Planned interval pre-determined per protocol.	80 characters

Sample Collected? ^(m)	Indicate whether or not the specimen is collected. YES - then the Sample ID (if applicable), Actual Start Date and Time should be entered NO UNKNOWN	Use pick list.
Actual Start Date	Enter the specimen collection date.	DD-MMM-YYYY
Actual Start Time	Enter the specimen collection time.	HH(24):MM
Time Interval ^(d)	Actual interval in minutes from the study agent start time.	6 digits
Parent Study Agent Assay 1	Enter the results of the parent assay for the study agent indicated in the study agent field. If the results are below the sensitivity threshold of the test, record the value as 0 (zero). Baseline assay values may be entered as Interval 0 (zero).	8 digits and 3 decimals
Parent Study Agent Assay 2	If the planned interval time point specimen was tested a second time, enter the results of the second parent assay for the study agent indicated in the study agent field.	8 digits and 3 decimals
Parent Study Agent Assay Mean	Enter the parent study agent assay mean concentration, if available. Note: This will not be completed if a second assay result is not available.	8 digits and 3 decimals
Parent Study Agent Assay UOM	Select the appropriate concentration units of measurement for the parent study agent assay(s) (e.g.: mg/dL or mmol/l).	Use pick list.
Metabolite Assay 1	If applicable, enter the first metabolite assay results for the parent study agent.	8 digits and 3 decimals

Metabolite Assay 2	If applicable, enter the second metabolite assay results in the biological samples.	8 digits and 3 decimals
Metabolite Assay Mean	Enter the metabolite assay mean concentration, if available. i Note: This will not be completed if a second assay result is not available.	8 digits and 3 decimals
Metabolite Assay UOM	Select the appropriate concentration units of measurement for the metabolite assays (e.g.: mg/dL or mmol/l).	Use pick list.

Code	Description	Resolutions
PHM01	Start Date is less than or equal to the Enrollment Date of informed consent signed.	Start Date must be after the Enrollment Date of informed consent signed.
PHM02	Start Date is in the future.	Enter a date earlier than or equal to the current date.
РНМ03	Sample ID number is repeated.	Sample ID number must be unique.
PHM05	Start Date / Time pair appears more than once – duplicate entry.	Remove the duplicate record or correct the Start Date / Time of one of them.
PHM06	Parent Study Agent UOM entered, but Assay 1, Assay 2 and Mean Concentration are missing.	Enter a Parent Study Agent Assay 1, Assay 2 and/or Mean Concentration.
PHM07	Parent Study Agent Assay 1, Assay 2 and/or Mean Concentration entered, but UOM is missing.	Enter the Parent Study Agent UOM.

PHM08	Metabolite UOM entered, but Assay 1, Assay 2 and Mean Concentration are missing.	Enter a Metabolite Assay 1, Assay 2 and Mean Concentration.
РНМ09	Metabolite Assay 1, Assay 2 and/or Mean Concentration entered, but UOM is missing.	Enter the Metabolite UOM.
PHM15	Stop Date is in the future.	Enter a date earlier than or equal to the current date.
PHM16	A Study Medication with a Medication/Agent matching the Pharmacokinetic with the same administration Date and Time was not found. Note: Study Medications with the following routes are ignored: PO, CIV and Topical.	Verify that the pharmacokinetics study agent administration is recorded on the study medication form.
PHM17	Collected Pharmacokinetics samples does not have corresponding sample ID, Date and Time.	Enter Sample ID, Actual Start Date and Time if 'Sample Collected' is 'YES'.

Derivations

Code	Field Name	Description
PHM1001	Course #	Course Number is derived from the Study Agent Start Date and the Course Initiation Start Dates.
PHM1002	Day in Course	Day in course is derived from the Study Agent Start Date and the Course Initiation Start Dates
PHM1003	Time Interval	Actual Time Interval is derived from the Actual Date and Time and the Start Date and Time.

Physical Exams - Courses


Contents

- Purpose
- Physical Exams Courses eCRF
- <u>Validations</u>
- Derivations
- Physical Exams Courses eCRF (Vital Signs tab)
- <u>Validations</u>
- Derivations

Purpose

Record physical exam results during treatment.

Physical Exams - Courses eCRF





Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the date the physical examination took place.	DD-MM-YYYY
PE Done? ^(m)	Indicate whether the physical examination was performed: YES - Yes NO - No Note: not applicable for CTMS.	Use pick list.
Date of Examination	Enter the date the physical examination took place.	DD-MM-YYYY

Day in Course^(d)^	Number of days since the beginning of the course is derived from the course initiation start date and examination date.	5 digits
Change from Baseline?	Indicate whether the finding results were changed compared with that of baseline: Y - Yes N - No	Use pick list.
	Note: not applicable for CTMS.	
Change from Previous Evaluation?	Indicate whether the finding results were changed compared with that of previous evaluation: Y - Yes N - No	Use pick list.
	Note: not applicable for CTMS.	
Body System	Predefined Body System. It cannot be changed.	text

Finding Results Indicate whether the finding results Use pick list. for the particular body system were either: N - Normal A - Abnormal X - Not Examined L - Not Applicable Comments are required for abnormal finding results. Note: Do not select "Normal" if the body system was not specifically assessed during the physical exam (i.e.: not mentioned in the progress note in the medical record). Any baseline body system with "Abnormal" Finding Results that remained unchanged must be re-entered in this case report form. 8 For CTMS reporting studies, L is reported as X. Comments If the finding results of a particular 200 characters (128 reported) body system have changed from baseline, give a brief description of the change. If choosing "Other", indicate the body or organ system missing from the list in the comment and include this for subsequent exams.

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Code	Description	Resolutions
PE01	Finding Results is marked abnormal and a comment is not specified.	Enter a comment or change the Finding Results selection.
PE03	Finding Results has changed from baseline (either from N to A or A to N or X to A), but comment is missing.	Review the Finding Results or enter a comment.
PE04	Date of Examination is in the future.	Enter an earlier date.
PE06	CTMS study has Comment length is greater than 128.	CTMS study should have comment no longer than 128.
PE07	PE is done but the Date of Examination is not provided.	Enter the Date of Examination.
PE08	PE is done and the response(s) to the change question(s) is/are 'Y', but the response to the evaluation section is absent.	Enter the evaluation section.

Derivations

Code	Field Name	Description
PE1001	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and examination date.

Physical Exams - Courses eCRF (Vital Signs tab)



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Vitals field.	DD-MMM-YYYY

Day in Course^(d)^	Indicates the day since the beginning of course the vital signs are related to based on their date and time.	5 digits
Date of Vitals^(m)^	Enter the date the vital signs were taken.	DD-MMM-YYYY
Time	Enter the time the vital signs were taken.	HH(24):MM
Notes	If necessary, enter some brief notes. Note: This information is not sent to the reporting agency.	200 characters
Performance Status (Karnofsky)	Select a value from the Karnofsky performance status scale. 0 - Dead 10 - Moribund 20 - Very Sick 30 - Hospitalized 40 - Disabled 50 - Frequent Assistance 60 - Occasional Assistance 70 - Self Care 80 - Effort 90 - Able 100 - Normal	Use pick list.
Status (Zubrod)	Select a value from the Zubrod/ECOG performance status scale. 0. Asymptomatic 1. Symptomatic, fully ambulatory 2. Symptomatic, in bed less than 50% of day 3. Symptomatic, in bed more than 50% of the day, but not bedridden 4. Bedridden	Use pick list.

Performance Status (Lansky)	Select a value from the Lansky performance status scale. 0 - Unresponsive 10 - No play; does not get out of bed 20 - Often sleeping; play entirely limited to very passive activities 30 - In bed; needs assistance even for quiet play 40 - Mostly in bed; participates in quiet activities 50 - Gets dressed but lies around much of the day; no active play; able to participate in all quiet play 60 - Up and around; but minimal active play; keeps busy with quieter activities 70 - Both greater restriction of and less time spent in play activity 80 - Active; but tires more quickly 90 - Minor restrictions in physically strenuous activity 100 - Fully active, normal	Use pick list.
Body Weight^(m)^	Enter the patient's weight only in kilograms. Use decimal places only for patients under 10kg. See Appendix 1 for conversion factors.	5 digits and 2 decimals
Height^(m)^	Enter the patient's height only in centimeters, to one decimal place. See Appendix 1 for conversion factors.	5 digits and 2 decimals
BSA^(m)^	Enter the patient's body surface area in m2 (to two decimal places) if needed for the calculation of study medication dose level. A nomogram for children's and adult's body surface area calculation can be found in Appendix 1. The following simple approximation may be used for persons of "normal" height and weight:	4 digit and 2 decimals
Temperature	Enter the patient's temperature only in Celsius, to one decimal place. See Appendix 1 for conversion factors.	8 digits and 3 decimals
Pulse	Enter the patient's pulse rate.	8 digits and 3 decimals

Respiration Rate	Enter the patient's respiration rate.	8 digits and 3 decimals
Systolic Blood Pressure	Enter the patient's systolic blood pressure.	8 digits and 3 decimals
Diastolic Blood Pressure	Enter the patient's diastolic blood pressure.	8 digits and 3 decimals
Pulse Oximetry	Enter the patient's pulse oximetry reading.	3 digits and 2 decimals

Code	Description	Resolutions
VIT01	Systolic Blood Pressure is less than Diastolic Blood Pressure.	Systolic Blood Pressure must be greater than Diastolic Blood Pressure.
VIT02	Two Vital Signs entries have the same Date and Time.	Correct the date and/or time.
VIT03	Entered BSA is not within 10% accuracy of the calculated BSA using the MIS formula.	Correct the BSA. The MIS BSA formula is: BSA (m²) = Height(cm)^0.725 x Weight(kg)^0.425 / 139.315
VIT04	Entered BSA is not within 10% accuracy of the calculated BSA using the Mosteller formula.	Correct the BSA. The Mosteller BSA formula is: BSA (m²) = (CCRClinicalIT2: Height(cm) x Weight(kg) / 3600)^½
VIT05	Vitals Date is in the future.	Enter a date that is equal to or prior to the current date.
VIT06, VIT07, VIT08, VIT09, VIT10, VIT11, VIT12, VIT13	Height, Weight, BSA, Temperature, Pulse, Respiration Rate, Systolic and/or Diastolic Blood Pressure are/is less than zero.	Height, Weight, BSA, Temperature, Pulse, Respiration Rate, Systolic Blood Pressure and Diastolic Blood Pressure must be greater than zero.
VIT14	Pulse Oximetry is out of range.	Pulse Oximetry must be an integer number between 0 and 100.
VIT15	Vitals (on cycle sections) have Date of Vitals outside the range of the cycle start and stop date.	Enter an appropriate date. Note: this does not apply for all protocol.

Derivations

Code	Field Name	Description
VIT1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the vital signs date.

Physical Exams - Screening

Purpose Physical Exams - Screening eCRF Validations Physical Exams - Screening eCRF (Vital Signs tab) Phys

Purpose

Record baseline physical exam results.

Physical Exams - Screening eCRF



Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the date the physical examination took place.	DD-MM-YYYY

PE Done? ^(m)	Indicate whether the physical examination was performed: YES - Yes NO - No Note: not applicable for CTMS.	Use pick list.
Date of Examination	Enter the date the physical examination took place.	DD-MM-YYYY
Body System	Predefined Body System. It cannot be changed.	text
Finding Results	Indicate whether the finding results for the particular body system were either: N - Normal A - Abnormal X - Not Examined L - Not Applicable Comments are required for abnormal finding results. Note: Do not select "Normal" if the body system was not specifically assessed during the physical exam (i.e.: not mentioned in the progress note in the medical record).	Use pick list.
	For CTMS reporting studies, L is reported as X.	

	Give a brief description for all abnormal finding results. If choosing "Other", indicate the body or organ system missing from the list in the comment and include this under both baseline and follow-up exams.	200 characters (128 reported)
--	--	-------------------------------

Validations

Code	Description	Resolutions
PE01	Finding Results is marked abnormal and a comment is not specified.	Enter a comment or change the Finding Results selection.
PE04	Date of Examination is in the future.	Enter an earlier date.
PE06	CTMS study has Comment length is greater than 128.	CTMS study should have comment no longer than 128.
PE07	PE is done but the Date of Examination is not provided.	Enter the Date of Examination.

Physical Exams - Screening eCRF (Vital Signs tab)



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Vitals field.	DD-MMM-YYYY
Date of Vitals^(m)^	Enter the date the vital signs were taken.	DD-MMM-YYYY

Time	Enter the time the vital signs were taken.	HH(24):MM
Notes	If necessary, enter some brief notes. i Note: This inform ation is not sent to the reporti ng agenc y.	200 characters
Performance Status (Karnofsky)	Select a value from the Karnofsky performance status scale. 0 - Dead 10 - Moribund 20 - Very Sick 30 - Hospitalized 40 - Disabled 50 - Frequent Assistance 60 - Occasional Assistance 70 - Self Care 80 - Effort 90 - Able 100 - Normal	Use pick list.
Status (Zubrod)	Select a value from the Zubrod/ECOG performance status scale. 0. Asymptomatic 1. Symptomatic, fully ambulatory 2. Symptomatic, in bed less than 50% of day 3. Symptomatic, in bed more than 50% of the day, but not bedridden 4. Bedridden	Use pick list.

Performance Status (Lansky)	Select a value from the Lansky performance status scale. 0 - Unresponsive 10 - No play; does not get out of bed 20 - Often sleeping; play entirely limited to very passive activities 30 - In bed; needs assistance even for quiet play 40 - Mostly in bed; participates in quiet activities 50 - Gets dressed but lies around much of the day; no active play; able to participate in all quiet play 60 - Up and around; but minimal active play; keeps busy with quieter activities 70 - Both greater restriction of and less time spent in play activity 80 - Active; but tires more quickly 90 - Minor restrictions in physically strenuous activity 100 - Fully active, normal	Use pick list.	
Body Weight^(m)^	Enter the patient's weight only in kilograms. Use decimal places only for patients under 10kg. See Appendix 1 for conversion factors.	5 digits and 2 decimals	
Height^(m)^	Enter the patient's height only in centimeters, to one decimal place. See Appendix 1 for conversion factors.	5 digits and 2 decimals	

BSA^(m)^	Enter the patient's body surface area in m2 (to two decimal places) if needed for the calculation of study medication dose level. A nomogram for children's and adult's body surface area calculation can be found in Appendix 1. The following simple approximation may be used for persons of "normal" height and weight:	4 digit and 2 decimals
Temperature	Enter the patient's temperature only in Celsius, to one decimal place. See Appendix 1 for conversion factors.	8 digits and 3 decimals
Pulse	Enter the patient's pulse rate.	8 digits and 3 decimals
Respiration Rate	Enter the patient's respiration rate.	8 digits and 3 decimals
Systolic Blood Pressure	Enter the patient's systolic blood pressure.	8 digits and 3 decimals
Diastolic Blood Pressure	Enter the patient's diastolic blood pressure.	8 digits and 3 decimals
Pulse Oximetry	Enter the patient's pulse oximetry reading.	3 digits and 2 decimals

Code	Description	Resolutions
VIT01	Systolic Blood Pressure is less than Diastolic Blood Pressure.	Systolic Blood Pressure must be greater than Diastolic Blood Pressure.
VIT02	Two Vital Signs entries have the same Date and Time.	Correct the date and/or time.

VIT03	Entered BSA is not within 10% accuracy of the calculated BSA using the MIS formula.	Correct the BSA. The MIS BSA formula is: BSA (m²) = Height(cm)^0.725 x Weight(kg)^0.425 / 139.315
VIT04	Entered BSA is not within 10% accuracy of the calculated BSA using the Mosteller formula.	Correct the BSA. The Mosteller BSA formula is: BSA (m²) = (CCRClinicalIT2: Height(cm) x Weight(kg) / 3600)^½
VIT05	Vitals Date is in the future.	Enter a date that is equal to or prior to the current date.
VIT06, VIT07, VIT08, VIT09, VIT10, VIT11, VIT12, VIT13	Height, Weight, BSA, Temperature, Pulse, Respiration Rate, Systolic and/or Diastolic Blood Pressure are/is less than zero.	Height, Weight, BSA, Temperature, Pulse, Respiration Rate, Systolic Blood Pressure and Diastolic Blood Pressure must be greater than zero.
VIT14	Pulse Oximetry is out of range.	Pulse Oximetry must be an integer number between 0 and 100.
VIT15	Vitals (on cycle sections) have Date of Vitals outside the range of the cycle start and stop date.	Enter an appropriate date. Note: this does not apply for all protocol.

Prior Radiation Supplement

Contents

- Purpose
- Prior Radiation Supplement eCRF
- Validations
- Derivations

Purpose

Record details of prior radiation therapy related to the disease being studies by the protocol or when the details would be clinically significant for the evaluation of this study.

Prior Radiation Supplement eCRF



Field Name	Description / Instructions	Format
Visit Date^(m)^	Note: If the information was obtained at multiple visits, please enter the date the form was completed.	DD-MMM-YYYY
Date of First Dose^(m)^	Enter the date of the first dose of the radiation therapy. Partial dates are acceptable when the day is not known.	DD-MMM-YYYY or MMM-YYYY

Date of Last Dose	Enter the date of the last dose of the radiation therapy. Partial dates are acceptable when the day is not known. Leave it blank if the therapy is currently being received. "Ongoing' will be reported to CTMS or CDS.	DD-MMM-YYYY, MMM-YYYY
Radiation Type^(m)^	Select the type of radiation therapy, e.g.: "proton beam", "external beam" or "implant".	Use pick list.
Other, Specify	Enter an explanation when 'Other, Specify' is selected as a 'Radiation Type'	100 Characters
Radiation Extent^(m)^	Select the extent of the radiation therapy as follows: Limited Radiation: therapy using ionizing radiation to a limited (<50%) portion of the body. Extensive Radiation: therapy using ionizing radiation to a significant portion of the body (>50%), e.g. cardiospinal, pelvic, or total-body. Radiation (NOS): Extent is not known.	Use pick list.
Site^(m)^	Select the site of the radiation therapy.	Use pick list.
Schedule	Select the radiation therapy schedule on which it was given.	24 characters
Total Dose	State the total radiation dose the patient received during the treatment period. Leave this field as well as the Total Dose UOM blank if the radiation therapy is ongoing.	8 characters
Total Dose UOM	Select the radiation dose units of measurement (e.g. cGy or rad, or cSv or rem).	Use pick list.

Best Response	Select the best response for the irradiated lesion. It applies to the type of therapy/intervation for which conventional response calls are appropriate. Leave this field blank if the radiation therapy is ongoing. CR - Complete Response PR - Partial Response MR - Minimal/Marginal Response SD - Stable Disease PD - Progressive Disease NE - Not Evaluable NA - Not Assessed UK - Unknown NR - No Response	Use pick list.
NonResponse Therapy Type	Select the therapy type for which the conventional response calls are not appropriate. AJ - Adjuvant Therapy PA - Palliative Therapy NJ - Neoadjuvant Therapy PR - Prophylaxis	Use pick list.

Validations

Code	Description	Resolutions
PRD01	Date of First Dose is greater than Date of Last Dose.	Enter a Date of First Dose that is equal to or earlier than the Date of Last Dose.
PRD02, PRD03	Date of First Dose and Date of Last Dose are in the future.	Enter a date that is equal to or earlier than the current date.
PRD04	Both Best Response and Nonresponse Therapy Type are present/absent.	One and only one fields should be entered.
PRD05	Prior Radiation Type 'Other Specify' and 'Other, Specify' field are not present together.	Enter 'Other Specify' if 'Other Specify' is selected as Prior Radiation Type.

Derivations

Code	Field Name	Description
PRD1001	Therapy Type	Derive Therapy Type Code based on matching Therapy Type

Prior Surgery Supplement

Contents

- Purpose
- Prior Surgery Supplement eCRF
- <u>Validations</u>

Purpose

Record details of prior surgery related to the disease being studies by the protocol or when the details would be clinically significant for the evaluation of this study.

Prior Surgery Supplement eCRF



Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the form was completed.	DD-MMM-YYYY
	i Note: If the information was obtained at multiple visits, please enter the date the form was completed.	
Date of Surgery ^(m)	Enter the date of the surgical procedure. Partial dates are acceptable when the day is not known.	DD-MMM-YYYY or MMM-YYYY

Procedure ^(m)	Enter the type of procedure performed to diagnose / to treat the patient's disease. Examples include, but not limited too: biopsy, node dissection, cytology, bone marrow biopsy, FNA (fine needle aspiration).	50 characters
Site ^(m)	Select the anatomical site of the procedure.	Use pick list.
Findings	Briefly describe the findings of the procedure.	24 characters
Residual Disease	Briefly describe the extent of the residual disease, if any, at the conclusion of the operation. (i.e.: microscopic, macroscopic).	24 characters
Therapeutic?	Select if the surgical procedure was performed with curative intent: Y - Yes N - No	Use pick list.

Code	Description	Resolutions
PSG01	Date of Surgery is in the future.	Enter a date that is equal to or earlier than the current date.

Prior Therapy Supplement


Contents

- Purpose
- Prior Therapy Supplement eCRF
- Validations
- Derivations

Purpose

Record details of prior therapies related to the disease being studies by the protocol or when the details would be clinically significant for the evaluation of this study as indicated on the Prior Treatment Summary case report form.

Prior Therapy Supplement eCRF



Field Name	Description / Instructions	Format
Visit Date^(m)^	Enter the date the form was completed (i.e. the date information was gathered).	DD-MMM-YYYY
Date of First Dose^(m)^	Enter the date of the first dose of the prior therapy. Partial dates are acceptable when the day is not known.	DD-MMM-YYYY or MMM-YYYY
Date of Last Dose	Enter the date of the last dose of the prior therapy. Partial dates are acceptable when the day is not known. Leave it blank if the treatment is currently being received. "Ongoing' will be reported to CTMS or CDS.	DD-MMM-YYYY, MMM-YYYY

Agent Name	Select the generic name of the agent that was used. Note: For standard regimen (multiple agents given as one regimen), enter one record for each agent.	Use pick list.
Schedule	Select the schedule on which the agent (or combination) was given.	24 characters
Total Dose	Enter the total dose of the agent.	8 characters
Total Dose UOM	Enter the total dose units of measurement.	12 digits
Total No.of Courses Administered	Enter the total number of cycles or courses of the specified drug or therapy agent administered to the patient as of the reported period	3 digits
Best Response	Select the best response encountered: CR - Complete Response MR - Minimal/Marginal Response NA - Not Assessed NE - Not Evaluable PD - Progressive Disease PR - Partial Response SD - Stable Disease UK - Unknown Leave this field blank if the treatment is ongoing.	Use pick list.
NonResponse Therapy Type	Select the therapy type for which the conventional response calls are not appropriate. AJ - Adjuvant Therapy PA - Palliative Therapy NJ - Neoadjuvant Therapy	Use pick list.

Therapy Type^(m)^	Select the appropriate type of prior therapy: Anti-Retroviral Therapy Antisense Bone Marrow Transplant Chemotherapy (NOS) Chemotherapy multiple agents systemic Chemotherapy non-cytotoxic Chemotherapy single agent systemic Gene Transfer Hormonal Therapy Drug and/or Immunotherapy Immunotherapy	Use pick list.
	Note: Do not use Immunot herapy for CTEP sponsored studies (CTMS and CDUS reporting). Oncolytic Virotherapy Vaccine Prior Therapy (NOS) Hematopoietic Stem Cell Transplantation Image Directed Local Therapy No prior Therapy	

Code	Description	Resolutions
PTS01	Date of First Dose is greater than Date of Last Dose.	Enter a Date of First Dose that is equal to or earlier than the Date of Last Dose.
PTS02, PTS03	Date of First Dose and Date of Last Dose are in the future.	Enter a date that is equal to or earlier than the current date.

PTS04 Both Best Response and Nonresponse Therapy Type are present/absent.	One and only one fields should be entered.
--	--

Code	Field Name	Description
PTS1001	Therapy Type	Derive Therapy Type Code based on matching Therapy Type

Prior Treatment Summary

Contents

- Purpose
- Prior Treatment Summary eCRF
- Validations
- Derivations

Purpose

Record whether or not the patient has received any treatments for each of the prior therapy types listed that are related to the disease being studies by the protocol.



Note: This CRF is only for CTEP-sponsored studies.

Details must be provided for the following on the appropriate Prior Therapy Case Report Form:

- 1. The last treatment prior to enrollment.
- 2. Any prior stem cell toxic therapy (e.g. mitomycin C) or cardiotoxic therapy (e.g. doxorubicin or other anthracycline) if relevant to the study agent.
- 3. Any therapies used to determine "extensive prior therapy" if specified in protocol.
- 4. Any therapies restricted by the protocol eligibility criteria, either specific drugs or number of prior therapies (e.g. no more than two prior chemotherapy regimens for metastatic disease).
- 5. Any therapies that are clinically significant for evaluation of the current study.
- 6. Additionally as required specifically by the protocol.

Prior Treatment Summary eCRF



let Date 11-Dec-2006 Slank C	mment		
TX COM			
			Dani
NUR TIBATIENT SURBARY			
	Any	#al Pror	
hungy lype	Thursday?	Cluniligners	Date of Last Deac
DIFTIOTHERAPY SHIPLE AGENT SYSTEMS			
DIEMOTHERAPY MULTIPLE AGENTS SYSTEMS			11 11 11 11 11 11 11 11 11 11 11 11 11
DIFLIOTHERAPY (NOS)			
ORHONAL THERAPY			
LIRGERY			
IRUG AND/OR MMUNOTHERAPY			
OVTENSIVE RADIATION			

Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the form was completed (i.e. the date information was gathered).	DD-MMM-YYYY

Therapy Type Name of the type of therapy. The Not applicable. appropriate list of therapy types is provided by CTMS. Note: "Limited Radiation" is therapy using ionizing radiation to a limited (<50%) portion of the body, while "Extensive Radiation" exposes a significant portion of the body (>50%), e.g. cardiospinal, pelvic, or total-body. Note: "Chemotherapy (NOS)" should be used only when it is not possible to determine whether the treatment was "single agent" or "multiple agent". Any Therapy?^(m) Indicate whether or not the patient Use pick list. has received any prior treatment for

the type of therapy listed.

must be provided.

N - No

Y - Yes - then Date of Last Dose

Number of Prior Chemotherapy Regimens ^{(u)(m)}	Enter the number of prior regimes received for chemotherapies types of therapy. Do not use for other types of therapy.	2 digits
	i Note: This field is only mandatory for studies that report data to CDS.	
Date of Last Dose	Enter the date of the last dose of the most recent prior treatment regimen for each therapy type. Partial dates are acceptable when the day is not known. Leave it blank if the treatment is currently being received and "Ongoing" will be reported to CTMS or CDS. For combination therapies, record the date of the last dose of medication for the combination.	DD-MMM-YYYY or MMM-YYYY

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only, (u) for CDS reporting only.

Validations

Code	Description	Resolutions
PTX02	Date of Last Dose is specified for a therapy type but the respective "Any Therapy?" is not checked 'Yes'.	Verify Date of Last Dose and/or "Any Therapy?".
PTX03	Date of Last Dose, which could be partial, is in the future.	Enter a Date of Last Dose that is equal to or earlier than the current date.
PTX04	Number of Prior Regimens is negative or not a number. (Note: only for studies reporting data to CDS)	Enter a number between 0 and 99 when applicable.
PTX05	Some of the 'Any Therapy?' answers were not provided.	Answer 'Y' or 'N' for all the 'Any Therapy?' questions.

Code	Field Name	Description
PTX1001	Therapy Type	Drive Therapy Type Code based on matching Therapy Type

Procedures


Contents

- Purpose
- Procedures eCRF
- Validations
- Derivations

Purpose

Record the results of the procedures that are performed as part of the protocol. All laboratory results are to be recorded on the appropriate lab CRF. All procedures that are done as a result of an adverse event are to be recorded on the concomitant measures CRF

Procedures eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number the procedure is related to based on their date and time.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course the procedure is related to based on their date and time.	5 digits

Date ^(m)	Enter the date that the procedure was done, not the date it was interpreted by the radiologist or investigator.	DD-MMM-YYYY
Time	Enter the time the procedure was done.	HH(24):MM
Procedure ^(m)	Select the procedure from the pick list. Note: For CTMS monitored protocols, these are the only Procedures sent: EKG Electrocardiogram CXR Chest X-ray BRNCHGRM Bronchogram UPGISER Upper GI Series LOGISER Lower GI Series SKELSURV Skeletal Survey HOLTMON Holter Monitor BONESCAN Bone Scan EEG Electroencephalogram BMCELLUTY Bone Marrow Cellularity UCASTS Urine Casts MUGASCAN Muga Scan ULTRASND Ultrasound CATSCAN CAT Scan MRI MRI X-RAY X-ray PETSCAN PET Scan CULTURE Culture	Use pick list.
Body Site ^(m)	Select the body site from the pick list. In the case of tests such as CATSCAN, MRI, and X-RAY record the applicable body site. For CAT Scan and MRI use thorax, abdomen, pelvis or brain.	Use pick list.

Abnormal Result? ^(m)	Select whether the finding results for the particular procedure / body site were either: A - Abnormal N - Normal	Use pick list.
Findings	If abnormal, enter as summary of the abnormal findings.	128 characters 200 characters for non-CTEP sponsored studies.

Validations

Code	Description	Resolutions
LBLL01	Procedure date is in the future.	Enter a date that is equal to or prior to the current date.
LBLL02, LBLL03	Findings were entered and Abnormal is not "A-Abnormal" or Abnormal is "A-Abnormal" and no brief description was entered in the Findings.	Abnormal Findings must have a brief description.

Code	Field Name	Description
LL1001	Course #	Course number is derived based on the course initiation start dates and the procedure date.
LL1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the procedure date.

Radiation


Contents

- <u>Purpose</u>
- Radiation eCRF
- Validations
- Derivations

Purpose

Record details of radiation therapy when specified by the protocol.

Radiation eCRF





Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Vitals field.	DD-MMM-YYYY
Day in Course ^(d)	Indicates the day since the beginning of course initiation. Derived from the course initiation start date.	5 digits
Start Date ^(m)	Enter the start date of the radiation therapy.	DD-MMM-YYYY
Start Time	Enter the start time of the radiation therapy.	HH(24):MM
Stop Date ^(m)	Enter the date of the last dose of the radiation therapy.	DD-MMM-YYYY

Stop Time	Enter the stop time of the radiation therapy.	HH(24):MM
Radiation Type ^(m)	Select the type of radiation therapy, e.g.: "proton beam", "external beam" or "implant".	Use pick list.
Other, Specify	Enter an explanation when 'Other, Specify' is selected as a 'Radiation Type'	100 character
Radiation Field	Select the site of the radiation therapy.	Use pick list.
Dose ^(m)	State the total radiation dose the patient received during the treatment period.	8 characters
Dose UOM ^(m)	Select the radiation dose units of measurement (e.g. cGy or rad, or cSv or rem).	Use pick list.
Dose per Fraction	Enter the fractionated dose of radiation therapy administered to a treatment field or site according to protocol.	5 digits
Total # of Fractions	Enter the number of dose-portions or fractions of radiation therapy actually administered.	4 digits
Elapsed Days	Enter the actual number of days radiation therapy was administered.	30 digits
Tx Delivery Location	Select the institute where the radiation therapy was administered.	Use pick list.

Validations

Code	Description	Resolutions
RAD01, RAD02	Date is in the future.	Enter a date that is equal to or earlier than the current date.
RAD03	Stop Date/Time is greater than Start Date/Time.	Correct the Start Date/Time or Stop Date/Time.

RAD04	Radiation Type 'Other Specify' and 'Other, Specify' field are not present together.	Enter 'Other Specify' if 'Other Specify' is selected as Radiation Type.
-------	---	---

Code	Field Name	Description
RAD1002	Day in Course	Derived from the respective course initiation start date.

Storage


Contents

- <u>Purpose</u>
- Storage eCRF

Purpose

Record the patient's sample collection.

Storage eCRF



Field Name	Description / Instructions	Format
Collected?	Indicate whether the research samples are collected: NO UnKNOWN YES	Use Pick List
Sample Collection Date	Enter the date of Sample collection	DD-MMM-YYYY
Comments	Enter comments applicable to the sample collection	200 characters

Legend: (d) derived field, (m) RDC mandatory, (c) for CTEP reporting only.

Study Medication Administration

Contents

- Purpose
- Study Medication Administration eCRF
- Validations
- Derivations

Purpose

Record study medication administration. Use a separate line for each medication and for each non-consecutive dose administration. Examples:

Oral daily agent:

Enter the start date of the cycle and then enter the date of last dose in the stop date field of the cycle. Note: start and stop times are not necessary for oral agents.

If the daily dosing is interrupted, enter the stop date, and on another line enter the start date if resumed during the same cycle. Enter the missed doses on the Missed Dose eCRF.

Agent administers on Days 1-5 weekly every 28 days

Enter four lines, one for each consecutive weekly doing.

If the daily dosing is interrupted, enter the stop date, and on another line enter the start date if resumed during the same cycle. Enter the missed doses on the Missed Dose eCRF.

Agent administer on Days 1, 3, 5 every 21 days

Three line entries are required

Continuous IV administration >24 hours

Enter start date and time of the infusion and when the infusion is completed (e.g., after 72 hours), enter the stop date and time.

Two IV agents are administer, one on Day 1 and the other on Days 1 and 15

Enter the two agents on separate lines for Day 1 and then on the third line, enter the Day 15 administration of the second drug.

Study Medication Administration eCRF



Field Name	Description / Instructions	Format
Visit Date ^(m)	Enter the date the course started.	DD-MMM-YYYY
Day in Course ^(d)	Indicates the day since the beginning of course initiation. Derived from the course initiation start date.	5 digits
Start Date ^(m)	Enter the date the medication was administered.	DD-MMM-YYYY
Start Time	For IV infusions only: Enter the start time of the infusion.	HH(24):MM
Stop Date	Enter the date the medication was discontinued.	DD-MMM-YYYY
Stop Time	For IV infusions only: Enter the stop time of the infusion.	HH(24):MM
Medication ^(m)	Note: The medication pick list incorporates all study medications, including pre and post medications specified in the protocol as part of the treatment. These medications should be documented in this case report form and NOT in the Concomitant Measures / Medications form.	Use pick list.

Planned Dose Level ^{(m)(c)}	Enter the amount of medication (a number) that was planned to be given for the dose level. It is not appropriate to record the dose level number such as "dose level 1". If the dose level is 100 mg/m2, then enter 100 for the dose level. The mg/m2 will be captured in the Planned UOM field. For dose levels that are expressed with scientific exponential units using powers of 10 such as vaccines and viral particles, enter as x10E. For example, dose level description is 2 x 106 PFUs, the dose level would be 2x10E6 and the PFUs would be noted in the Planned UOM (Units of Measurement) field.	8 digits & 3 decimals
	Note: for non-CTEP studies, this field may be removed.	
Planned UOM ^{(m)(c)}	Select the Planned Dose Level unit of measurement. Note: for non-CTEP studies, this field may be removed.	Use pick list.
Planned Schedule ^{(m)(c)}	Select the schedule of medication administration as indicated in the protocol. Note: for non-CTEP studies, this field may be removed.	Use pick list.
Planned Route ^(m)	Select the route from the list.	Use pick list.

Actual Total Dose ^(m)	Enter the total actual dose given for the medication name entered above for the time period encompassed by the duration. See Actual UOM below for the units of measure of the actual dose. i Note: In the case of medications (such as vaccines and viral particles) where the dose is expressed with scientific exponential units using powers of 10, record (for example) 106 as 1X10E6.	8 digits & 3 decimals
Actual Dose UOM ^(m)	Select the Actual Dose Level unit of measurement.	Use pick list.
Lot #	Enter the Lot Number for the medication supply.	24 characters
Duration ^(m)	Enter the duration calculated from the start date/time and stop date/time. Note: for non-CTEP studies, this field is not mandatory.	6 digits & 2 decimals
Duration UOM ^(m)	Select the units of measurement so that the duration can be derived. DY - Days HR - Hours MN - Minutes MO - Months Wk - Weeks	Use pick list.

Validations

Code	Description	Resolutions
SD01, SD03	Start Date and/or Stop Dare are/is in the future.	Enter a date earlier than or equals to the current date.
SD04	Stop Date/Time is prior to Start Date/Time.	Correct the Start Date/Time or Stop Date/Time.
SD05	Duplicate Medication records exist.	A unique entry for Medication, Start Date/Time and Stop Date/Time is required.
SD06, SD07, SD08, SD09	Overlapping start and stop dates/times for the same medication.	Review the medications in question and their respective start and stop dates/times.
SD10	Start Time or Stop Time is missing.	Both Start and Stop Time are required or optional.

Code	Field Name	Description
SD1001	Day in Course	Derived from the respective course initiation start date.

Surgery

Contents

- <u>Purpose</u>
- Surgery eCRF
- <u>Validations</u>
- Derivations

Purpose

Record details of surgery performed as part of the treatment when required by the protocol.

Surgery eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Vitals field.	DD-MMM-YYYY
Day in Course (d)	Indicates the day since the beginning of course the cardiac ejection fraction results are related to based on their date and time.	5 digits
Date of Surgery (m)	Enter the date of the surgical procedure.	DD-MMM-YYYY

Procedure (m)	Enter the type of procedure performed to diagnose / to treat the patient's disease. Examples include, but not limited too: biopsy, node dissection, cytology, bone marrow biopsy, FNA (fine needle aspiration).	100 characters
Findings	Briefly describe the findings of the procedure.	24 characters
Residual Disease	Briefly describe the extent of the residual disease, if any, at the conclusion of the operation. (i.e.: microscopic, macroscopic).	24 characters
Were Margin Clear?	Select the results of tissue margin examination.	Use pick list.
Margin Comments	Enter the comment for margin examination.	200 characters
Total Lymph Nodes Involved	Enter the number of lymph nodes involved with disease as determined by pathologic examination.	5 digits
Total Lymph Nodes Evaluated	Enter the total number of lymph nodes removed and pathologically assessed for disease.	5 digits

Validations

Code	Description	Resolutions
SUG01	Date of Surgery is in the future.	Enter a date that is equal to or earlier than the current date.

Code	Field Name	Description
SUG1002	Day in Course	Derived from the respective course initiation start date.

Survival

Contents


- Purpose
- Survival eCRF
- Validations

Purpose

Use this form to record information about the patient's death and autopsy results if applicable.

Note: Only the Date of Death is sent to CTMS if there is an indication, on the Follow-up case report form, that the patient has received further treatment. All the fields still need to be entered though.

Survival eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Last Contact field.	DD-MMM-YYYY
Date of Death ^(m)	Enter the date the patient has died.	DD-MMM-YYYY

Cause of Death (Presumed) ^(m)	If the patient died without intervening therapy specific to the disease for which the patient was put on study, this section should be completed. Categorize the cause as due to: M - Malignant Disease T - Toxicity from Protocol Treatment I - Infection O - Other (Explain) If "Other" is checked, enter a succinct description of the presumed cause of death on the field "Explain 'Other' Presumed Cause of Death".	Use pick list.
Explain 'Other' Cause of Death (Presumed)	Enter a succinct description if option "Other" is selected as presumed cause of death. For example: Concurrent illness/MI".	24 characters
Autopsy Results Available? ^(m)	Select an option indicating whether the results of an autopsy are available. Y - Yes - Autopsy done and results available. N - No - Autopsy not done or autopsy done, but results not yet available. U - Unknown - Do not know if an autopsy was done. If the autopsy results are still pending, select "No" and update this CRF when the results are available.	Use pick list.

Cause of Death (Autopsy Finding)	If an autopsy was performed and a cause of death was determined at autopsy, it should be categorized according to: M - Malignant Disease T - Toxicity from Protocol Treatment I - Infection O - Other Only one category should be checked. If "Other" is checked, enter a succinct description of the autopsy finding cause of death on the field "Explain 'Other' Autopsy Finding Cause of Death".	Use pick list.
Explain 'Other' Cause of Death (Autopsy Finding)	If option "Other" is selected as autopsy finding cause of death, enter a succinct description, i.e., MI.	24 characters
Sites of Disease (Autopsy Finding)	Select the major sites of malignant disease involvement found at the autopsy, i.e., heart, brain, lungs, etc.	Use pick list.

Validations

Code	Description	Resolutions
SUR01	Date of Death is in the Future.	Enter a Date of Death that is earlier than or equal to the current date.
SUR02	Autopsy Results Available is set to "Yes", but Cause of Death (Autopsy Finding) is not specified.	Cause of Death (Autopsy Finding) must be provided when the Autopsy Results Available is set to "Yes".
SUR03	Autopsy Results Available is not set to "Yes" and some, or all, of the other autopsy fields have been entered.	Verify Autopsy Results Available and the other autopsy fields.
SUR04	Cause of Death (Autopsy Finding) is "Other" and Explain 'Other' Cause of Death (Autopsy Finding) is not specified.	Verify Cause of Death (Autopsy Finding) and Explain 'Other' Cause of Death (Autopsy Finding) fields.

SUR05	Explanation provided in Explain 'Other' Cause of Death (Autopsy Finding), but Cause of Death (Autopsy Finding) is not "Other".	Cause of Death (Autopsy Finding) must be 'Other' when an explanation is provided in the Explain 'Other' Cause of Death (Autopsy Finding) field.
SUR06	Cause of Death (Presumed) is "Other" and Explain 'Other' Cause of Death (Presumed) is missing.	An 'Other' Cause of Death (Presumed) requires an explanation in the Explain 'Other' Presumed Cause of Death field.
SUR07	Explanation provided in Explain 'Other' Cause of Death (Presumed), but Cause of Death (Presumed) is not "Other".	Cause of Death (Presumed) must be 'Other' when an explanation is provided in the Explain 'Other' Presumed Cause of Death field.
SUR08	Date of Death is greater than 30 days past Off Study Date.	Survival eCRF is not applicable as patient is off study.

Transfusions


Contents

- Purpose
- Transfusions eCRF
- <u>Validations</u>
- Derivations

Purpose

Record the patient's received transfusions.

Transfusions eCRF



Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number the transfusion is related to based on their date and the Course Initiation start dates.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course the transfusion is related to based on their date and the Course Initiation start dates.	5 digits
Date ^(m)	Enter the date that the transfusion was done.	DD-MMM-YYYY

Time ^(m)	Enter the time the transfusion was done.	HH(24):MM
Transfusion Component ^(m)	Select the transfusion component from the pick list.	Use pick list.
(#) of Units ^(m)	Enter the blood component number of units transfused (in Units)	3 digits

Validations

Code	Description	Resolutions
TF01	Transfusion date is in the future.	Enter a date that is equal to or prior to the current date.
TF02	Two or more transfusions with the same date and time.	There can only be one transfusion for a date and time.

Code	Field Name	Description
TF1001	Course #	Course number is derived based on the course initiation start dates and the transfusion date.
TF1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the transfusion date.

Urinary Excretions

Contents

- Purpose
- Urinary Excretion eCRF
- Validations
- Derivations


Purpose

Record detailed information about the collection of urine samples for analysis of the presence and quantity of the study medication and/or its metabolites.



Note: This CRF will be put on the cycle section.

Urinary Excretion eCRF





Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Dosing field.	DD-MMM-YYYY
Course Number ^(d)	Indicates the course number that this urinary excretion sample is related to as derived from the course initiation start date.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course that this urinary excretion sample is related to as derived from the course initiation start date.	5 digits
Start Date of Dosing ^(m)	Enter the date the study agent was administered.	DD-MMM-YYYY

Start Time of First Injection ^(m)	Enter the time of the first injection of the study agent, or if appropriate, for taking the study agent via any "non-IV" route of administration (for example, enter the time that the agent is administered orally or rectally).	HH(24):MM
Study Agent ^(m)	Enter the name of the study agent (investigational or commercial) which is the subject of the urinary excretion study. i Note: Only one study agent is allowed per case report form. Separate forms should be used when more than one study agent is being studied.	Use pick list.
Stop Date of Dosing	Enter the date the study agent administration was stopped. i Note: This field will be used for infusional therapies only.	DD-MMM-YYYY
Stop Time of First Injection	Enter the stop time of the first injection of the study agent, or if appropriate, for taking the study agent via any "non-IV" route of administration (for example, enter the time that the agent is administered orally or rectally). i Note: This field will be used for infusional therapies only.	HH(24):MM
Planned Interval	Planned interval pre-determined per protocol.	80 characters

Sample Collected? ^(m)	Indicate whether or not the specimen is collected. YES - then the Start Date, Time and Urine Volume should be entered NO UNKNOWN	Use pick list.
Start Date	Enter the collection start date.	DD-MMM-YYYY
Start Time	Enter the collection start time even if the assay results are not available.	HH(24):MM
Stop Date	Enter the collection end date.	DD-MMM-YYYY
Stop Time	Enter the collection end time even if the assay results are not available.	HH(24):MM
Urine Volume	Enter the urine volume collected in milliliters.	4 digits.
Parent Study Agent Assay 1	Enter the first parent study agent assay results in the biological samples. If results are not available, record at least the collection times on the case report form.	8 digits and 3 decimals
Parent Study Agent Assay 2	Enter the second parent study agent assay results in the biological samples. If results are not available, record at least the collection times on the case report form.	8 digits and 3 decimals
Parent Study Agent Assay Mean Concentration	Enter the parent study agent assay mean concentration, if available.	8 digits and 3 decimals
Parent Study Agent in Void	Enter the parent study agent assay in void results in the biological samples. If results are not available, record at least the collection times on the case report form.	8 digits and 3 decimals
Parent Study Agent UOM	Select the appropriate Study Agent units of measurement (e.g.: mg/dL or mmol/l).	Use pick list.

Metabolite Assay 1	Enter the first metabolite assay results in the biological samples. If results are not available, record at least the collection times on the case report form.	8 digits and 3 decimals
Metabolite Assay 2	Enter the second metabolite assay results in the biological samples. If results are not available, record at least the collection times on the case report form.	8 digits and 3 decimals
Metabolite Mean Concentration	Enter the metabolite mean concentration, if available.	8 digits and 3 decimals
Metabolite in Void	Enter the metabolite in void results in the biological samples. If results are not available, record at least the collection times on the case report form.	8 digits and 3 decimals
Metabolite UOM	Enter the appropriate Metabolite units of measurement (e.g.: mg/dL or mmol/l).	Use pick list.

Validations

Code	Description	Resolutions
UE01, UE02, UE07, UE15	Urinary excretion dates are in the future.	Enter dates that are equal to or prior to the current date.
UE06	Collection End Date/Time is prior to the collection Start Date/Time.	Collection End Date/Time must be after the collection Start Date/Time.
UE08	Start Date / Time and Stop Date / Time pair appears more than once – duplicate entry.	Remove the duplicate record or correct the Start Date / Time and Stop Date / Time of one of them.
UE11	Study Agent UOM entered, but Assay 1, Assay 2, Mean Concentration and Amount in Void are missing.	Enter a Study Agent Assay 1, Assay 2, Mean Concentration and/or Amount in Void.

UE12	Study Agent Assay 1, Assay 2, Mean Concentration and/or Amount in Void entered, but UOM is missing.	Enter the Study Agent UOM.
UE13	Metabolite UOM entered, but Assay 1, Assay 2, Mean Concentration and Amount in Void are missing.	Enter a Metabolite Assay 1, Assay 2, Mean Concentration and/or Amount in Void.
UE14	Metabolite Assay 1, Assay 2, Mean Concentration and/or Amount in Void entered, but UOM is missing.	Enter the Metabolite UOM.
UE16	Collected Urinary Excretion sample does not have corresponding Start Date, Time and Urine volume.	Enter Start Date, Time and Urine Volume if 'Sample Collected' is 'YES'.

Code	Field Name	Description
UE1001	Course #	Course number is derived based on the course initiation start dates and the infection episode onset date.
UE1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the infection episode onset date.

Vital Signs

Contents

- Purpose
- Vital Signs eCRF
- Validations
- Derivations


Purpose

Record the patient's Vital Signs while on study. Please note that if Vital Signs are taken as a part of protocol specific Physical Exam, record those Vital Signs on the Physical Exam eCRF.

0

Note: This eCRF is mandatory for all CTEP sponsored CTMS monitored studies.

Vital Signs eCRF





Field Name	Description / Instructions	Format
Visit Date	The Visit Date is optional on this case report form. Hit the "Tab" key to leave it empty and move to the Date of Vitals field.	DD-MMM-YYYY
Course # ^(d)	Indicates the course number the vital signs are related to based on their date and time.	5 digits
Day in Course ^(d)	Indicates the day since the beginning of course the vital signs are related to based on their date and time.	5 digits

Date of Vitals ^(m)	Enter the date the vital signs were taken.	DD-MMM-YYYY	
Time	Enter the time the vital signs were taken.	HH(24):MM	
Notes	If necessary, enter some brief notes. Note: This inform ation is not sent to the reporting agency.	200 characters	
Performance Status (Karnofsky)	Select a value from the Karnofsky performance status scale. 0 - Dead 10 - Moribund 20 - Very Sick 30 - Hospitalized 40 - Disabled 50 - Frequent Assistance 60 - Occasional Assistance 70 - Self Care 80 - Effort 90 - Able 100 - Normal	Use pick list.	
Status (Zubrod)	Select a value from the Zubrod/ECOG performance status scale. 0. Asymptomatic 1. Symptomatic, fully ambulatory 2. Symptomatic, in bed less than 50% of day 3. Symptomatic, in bed more than 50% of the day, but not bedridden 4. Bedridden	Use pick list.	

Performance Status (Lansky)	Select a value from the Lansky performance status scale. 0 - Unresponsive 10 - No play; does not get out of bed 20 - Often sleeping; play entirely limited to very passive activities 30 - In bed; needs assistance even for quiet play 40 - Mostly in bed; participates in quiet activities 50 - Gets dressed but lies around much of the day; no active play; able to participate in all quiet play 60 - Up and around; but minimal active play; keeps busy with quieter activities 70 - Both greater restriction of and less time spent in play activity 80 - Active; but tires more quickly 90 - Minor restrictions in physically strenuous activity 100 - Fully active, normal	Use pick list.
Body Weight ^(m)	Enter the patient's weight only in kilograms. Use decimal places only for patients under 10kg. See Appendix 1 for conversion factors.	5 digits and 2 decimals
Height ^(m)	Enter the patient's height only in centimeters, to one decimal place. See Appendix 1 for conversion factors.	5 digits and 2 decimals

BSA ^(m)	Enter the patient's body surface area in m2 (to two decimal places) if needed for the calculation of study medication dose level. A nomogram for children's and adult's body surface area calculation can be found in Appendix 1. The following simple approximation may be used for persons of "normal" height and weight:	5 digit and 3 decimals
Temperature	Enter the patient's temperature only in Celsius, to one decimal place. See Appendix 1 for conversion factors.	3 digits and 1 decimal
Pulse	Enter the patient's pulse rate.	3 digits
Respiration Rate	Enter the patient's respiration rate.	3 digits
Systolic Blood Pressure	Enter the patient's systolic blood pressure.	8 digits and 3 decimals
Diastolic Blood Pressure	Enter the patient's diastolic blood pressure.	8 digits and 3 decimals
Pulse Oximetry	Enter the patient's pulse oximetry reading.	3 digits and 2 decimals

Validations

Code	Description	Resolutions
VIT01	Systolic Blood Pressure is less than Diastolic Blood Pressure.	Systolic Blood Pressure must be greater than Diastolic Blood Pressure.
VIT02	Two Vital Signs entries have the same Date and Time.	Correct the date and/or time.

VIT03	Entered BSA is not within 10% accuracy of the calculated BSA using the MIS formula.	Correct the BSA. The MIS BSA formula is: BSA (m²) = Height(cm)^0.725 x Weight(kg)^0.425 / 139.315
VIT04	Entered BSA is not within 10% accuracy of the calculated BSA using the Mosteller formula.	Correct the BSA. The Mosteller BSA formula is: BSA (m²) = (Height(cm) x Weight(kg) / 3600)^½
VIT05	Vitals Date is in the future.	Enter a date that is equal to or prior to the current date.
VIT06, VIT07, VIT08, VIT09, VIT10, VIT11, VIT12, VIT13	Height, Weight, BSA, Temperature, Pulse, Respiration Rate, Systolic and/or Diastolic Blood Pressure are/is less than zero.	Height, Weight, BSA, Temperature, Pulse, Respiration Rate, Systolic Blood Pressure and Diastolic Blood Pressure must be greater than zero.
VIT14	Pulse Oximetry is out of range.	Pulse Oximetry must be an integer number between 0 and 100.
VIT15	Vitals (on cycle sections) have Date of Vitals outside the range of the cycle start and stop date.	Note: this does not apply for all protocol.

Code	Field Name	Description
VIT1001	Course #	Course number is derived based on the course initiation start dates and the vital signs date.
VIT1002	Day in Course	Number of days since the beginning of the course is derived from the course initiation start date and the vital signs date.

Conversion Tables

Conversion Factors

Unknown macro: {table-plus}

Height	Weight	Temperature
Ht (in) x 2.54=Ht (cm)	Wt (lb) ÷ 2.2=Wt (kg)	(T (F)-32) * 5 ÷ 9=T (C)
60 in = 152.4 cm	100 lb = 45.5 kg	105.0 F = 40.6 C
61 in = 154.9 cm	105 lb = 47.7 kg	104.5 F = 40.3 C
62 in = 157.5 cm	110 lb = 50.0 kg	104.0 F = 40.0 C
63 in = 160.0 cm	115 lb = 52.3 kg	103.5 F = 39.7 C
64 in = 162.6 cm	120 lb = 54.5 kg	103.0 F = 39.4 C
65 in = 165.1 cm	125 lb = 56.8 kg	102.5 F = 39.2 C
66 in = 167.6 cm	130 lb = 59.1 kg	102.0 F = 38.9 C
67 in = 170.2 cm	135 lb = 61.4 kg	101.5 F = 38.6 C
68 in = 172.7 cm	140 lb = 63.6 kg	101.0 F = 38.3 C
69 in = 175.3 cm	145 lb = 65.9 kg	100.5 F = 38.1 C
70 in = 177.8 cm	150 lb = 68.2 kg	100.0 F = 37.8 C
71 in = 180.3 cm	155 lb = 70.5 kg	99.5 F = 37.5 C
72 in = 182.9 cm	160 lb = 72.7 kg	99.0 F = 37.2 C
73 in = 185.4 cm	165 lb = 75.0 kg	98.5 F = 36.9 C
74 in = 188.00 cm	170 lb = 77.3 kg	98.0 F = 36.7 C
75 in = 190.5 cm	175 lb = 79.5 kg	97.5 F = 36.4 C

These examples are intended as a guide only. Please use the formula provided for a precise conversion.

- Nomogram for determining Body Surface of Adults from the formula of Du Bois and Du Bois, Arch. Intern. Med., 17, 863 (1916)
- 1 Nomogram for determining Body Surface of Children from the formula of Du Bois and Du Bois, Arch. intern. Med., 17, 863 (1916)

Holphe	Dode ou hard	Non
- 20 - E 10 II	g-188 =*	44110 mg - 200
	-129	10-5-20
	- ter	120-30
¥-11		10-5-20
ge - 11	-1.00	18.5
_ E:	- 146	130.40
m = 1	E _{1M}	12-6
123 - 194	128	110-2
20 - 0	-128	100-2-10
3.0	- 1.0	100-3-18
M1 - 10	100	×2.1
	141	5
100-1-10	150	
£:	- 131	-5-7
3	-131	0.3
76 T-H		
3.0	-10	· 1
10	Ene	2-0
1-8	F.,,	7-14
10-2-11		* 1
1 · A	- 10	3.00
70-10	1.2	0 E 0
		- 5
100-7-11	-131	N-2-10
	- LM	2
25	E-18	50-2-11
+	-13	-3-1e
100-1-01		.3.0
€.,		3.0
10-1-11	F-1.8	1
ž.,,	- 10	0-5
	1	- 돌이
	LOS	5-8
3-41	-00	n-2
30-1-A	E	3.0
2.0	- 09	
3-4	Econo	
- Mil	-30	4,000

Appendix II - Useful References

Under development.

Appendix III - Lab Panels

Appendix III - Lab Panels				
Edit Document	Com	C3D Lab Test Name	Tretont	
Lap Panel	Seq		Intent	
BLOOD CHEMISTRIES	1	SODIUM_SER	Sodium, Serum	
BLOOD CHEMISTRIES	2	POTASSIUM_SER	Potassium, Serum	
BLOOD CHEMISTRIES	3	CHLORIDE_SER	Chloride, Serum	
BLOOD CHEMISTRIES	4	GLUCOSE_SER	Glucose, Serum	
BLOOD CHEMISTRIES	5	BICARB_SER	Bicarbonate, Serum	
BLOOD CHEMISTRIES	6	GLUCOSE_FAST_SER	Glucose, Fasting, Serum	
BLOOD CHEMISTRIES	7	GLUCOSE_NONFAST_SER	Glucose, Non-fasting, Serui	
BLOOD CHEMISTRIES	8	BUN_SER	Blood Urea Nitrogen (BUN	
BLOOD CHEMISTRIES	9	ALBUMIN_SER	Albumin, Serum	
BLOOD CHEMISTRIES	10	CALCIUM_SER	Calcium, Serum	
BLOOD CHEMISTRIES	11	MAGNESIUM_SER	Magnesium, Serum	
BLOOD CHEMISTRIES	12	PHOSPHATE_SER	Phosphate (inorganic Phosp	
BLOOD CHEMISTRIES	13	ALK_PHOS_SER	Alkaline Phosphatase, Serui	
BLOOD CHEMISTRIES	14	ALT_SGPT_SER	Alanine Aminostransferase	
BLOOD CHEMISTRIES	15	AST_SGOT_SER	Aspartate Aminotransferase	
BLOOD CHEMISTRIES	16	BILIRUB_TTL_SER	Bilirubin, Total, Serum	
BLOOD CHEMISTRIES	17	BILIRUB_DIR_SER	Bilirubin, Direct, Serum	
BLOOD CHEMISTRIES	18	LDH_SER	Lactate Dehydrogenase (LD	
BLOOD CHEMISTRIES	19	CK_SER	Creatinine Kinase (CK), Ser	
BLOOD CHEMISTRIES	20	URATE_SER	Urate (Uric Acid), Serum	
BLOOD CHEMISTRIES	21	CREATININE_SER	Creatinine, Serum	
BLOOD CHEMISTRIES	22	TTL_PROTEIN_SER	Total Protein, Serum	
BLOOD GASES	1	PH_BLDART	pH, Arterial Blood	
BLOOD GASES	2	PCO2_BLDART	Percent Carbon Dioxide (pC	
BLOOD GASES	3	PO2_BLDART	Percent Oxygen (pO2), Arte	
BLOOD GASES	4	HCO3_BLDART	Bicarbonate (HCO3), Arteri	
BLOOD GASES	5	COHGB_BLDART	Carboxyhemoglobin, Arteri	
BONE MARROW	1	PROMYELOCYTE_PC_MAR	Promyelocytes, %, Bone Ma	
BONE MARROW	1	PROMYELOCYTE_PC_MAR	Promyelocytes, %, Bone Ma	
BONE MARROW	2	MYELOCYTE_PC_MAR	Myelocytes, %, Bone Marro	
BONE MARROW	3	METAMYELOCYTE_PC_MAR	Metamyelocytes, %, Bone N	
BONE MARROW	3	METAMYELOCYTE_PC_MAR	Metamyelocytes, %, Bone N	
BONE MARROW	4	LYMPH_PC_MAR	Lymphocytes, %, Bone Mar	
BONE MARROW	5	MONO_PC_MAR	Monocytes, %, Bone Marro	
BONE MARROW	6	PLASMA_CELL_PC_MAR	Plasma Cells, %, Bone Mari	
BONE MARROW	7	M_RATING_MAR	FAB Marrow Rating, Bone	
BONE MARROW	8	RETIC_PC_MAR	Reticulocytes, %, Bone Mar	
BONE MARROW	8	RETIC_PC_MAR	Reticulocytes, %, Bone Mar	
BONE MARROW	9	MEGAKARYOCYTE_PC_MAR	Megakaryocytes, %, Bone N	
CHIMERISM LAB	1	STR_C_DON_PC_BM	Nonseparated Short Tandem	
CHIMERISM LAB	2	STR_C_D1_CD14_PC_BLD	Short Tandem Repeat Chim	

CHIMERISM LAB	3	STR_C_D2_CD14_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	4	STR_C_R_CD14_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	5	STR_C_D1_CD19_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	6	STR_C_D2_CD19_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	7	STR_C_R_CD19_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	8	STR_C_D1_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	9	STR_C_D2_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	10	STR_C_R_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	11	STR_C_1M_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	12	STR_C_2M_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	13	STR_C_RM_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	14	STR_C_1NK_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	15	STR_C_2NK_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	16	STR_C_RNK_DC_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	17	STR_CHI_MDONR_PC_BM	Short Tandem Repeat Chimer
CHIMERISM LAB	18	STR_C_MDON1_PC_BM	Short Tandem Repeat Chimer
CHIMERISM LAB	19	STR_C_MDON2_PC_BM	Short Tandem Repeat Chimer
CHIMERISM LAB	20	STR_CHI_MDONR_PC_OS	Short Tandem Repeat Chimer
CHIMERISM LAB	21	STR_C_MDON1_PC_OS	Short Tandem Repeat Chimer
CHIMERISM LAB	22	STR_C_MDON2_PC_OS	Short Tandem Repeat Chimer
CHIMERISM LAB	23	STR_CHI_PC_OS	Short Tandem Repeat Chimer
CHIMERISM LAB	24	STR_C_MDON1_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB	25	STR_C_MDON1_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB CHIMERISM LAB	26	STR_CHI_MDONR_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB CHIMERISM LAB	27	STR_C_MD_D1M_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB	28		Short Tandem Repeat Chimer
CHIMERISM LAB	29	STR_C_MD_D2M_PC_WBC STR_C_MD_R_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB	30		Short Tandem Repeat Chimer
CHIMERISM LAB	31	STR_C_MD_D1_PC_BLD	Short Tandem Repeat Chimer
	32	STR_C_MD_D2_PC_BLD STR_C_D1_NK_PC_BLD	Short Tandem Repeat Chimer
CHIMERISM LAB	33		1
CHIMERISM LAB CHIMERISM LAB	_	STR_C_D2_NK_PC_BLD	Short Tandem Repeat Chimer Short Tandem Repeat Chimer
	34	STR_C_R_NK_PC_BLD	1
CHIMERISM LAB	35	STR_C_PC_OS_1	Short Tandem Repeat Chimer
CHIMERISM LAB	36	STR_C_PC_OS_2	Short Tandem Repeat Chimer
CHIMERISM LAB	37	STR_C_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB	38	STR_C_D_CD3_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB	39	STR_C_D_M_PC_WBC	Short Tandem Repeat Chimer
CHIMERISM LAB	40	STR_C_DON_PC_BLD	Nonseparated Short Tandem 1
CHIMERISM LAB	41	STR_CHI_PC_BLD	Nonseparated Short Tandem 1
CHIMERISM LAB	42	STR_CHI_PC_BM	Nonseparated Short Tandem 1
COAGULATION	1	PT_BLD	Prothrombin Time (PT), Bloo
COAGULATION	2	PTT_BLD	Partial Thromboplastin Time
COAGULATION	3	INR_PT_BLD	International Normalized Rati
COAGULATION	4	FIBRINOGEN_BLD	Fibrinogen, Blood
COAGULATION	5	THROMBIN_TM_BLD	Thrombin Time, Blood
CSF	1	WBC_NUM_CSF	White Blood Cells (WBC), #,
CSF	2	RBC_NUM_CSF	Red Blood Cells (RBC), #, Co

CSF	3	OTHER_CELL_CSF	Other Cell Count, Cerebrospi
CSF	4	LYMPH_PC_CSF	Lymphocytes, %, Cerebrospin
CSF	5	CELL_CT_CSF	Cell Count, Cerebrospinal Flu
CSF	6	MBP_CSF	Myelin Basic Protein, Cerebro
CSF	7	GLUCOSE_CSF	Glucose, CSF
CSF	8	COLOR_CSF	Color, Cerebrospinal Fluid
CSF	9	APPEAR_CSF	Appearance, Cerebrospinal Fl
HEMATOLOGY	1	WBC_NUM_BLD	White Blood Cells (WBC), #,
HEMATOLOGY	2	RBC_NUM_BLD	Red Blood Cells (RBC), #, Bl
HEMATOLOGY	3	HGB_BLD	Hemoglobin, Blood
HEMATOLOGY	4	HCT_BLD	Hematocrit, %, Blood
HEMATOLOGY	5	MCV_RBC	Mean Corpuscular Volume (N
HEMATOLOGY	6	MCHC_RBC	Mean Corpuscular Hemoglob
HEMATOLOGY	7	MCH_RBC	Mean Corpuscular Hemoglob
HEMATOLOGY	8	RDW_RBC	Red Cell Distribution Width (
HEMATOLOGY	9	PLATELET_BLD	Platelets, Blood
HEMATOLOGY	10	NRBC_NUM_BLD	Nucleated Red Blood Cells (N
HEMATOLOGY	11	NEUT_PC_BLD	Neutrophils, %, Blood
HEMATOLOGY	12	BAND_PC_BLD	Neutrophil Bands, %, Blood
HEMATOLOGY	13	LYMPH_PC_BLD	Lymphocytes, %, Blood
HEMATOLOGY	14	MONO_PC_BLD	Monocytes, %, Blood
HEMATOLOGY	15	EOSINOPHIL_PC_BLD	Eosinophils, %, Blood
HEMATOLOGY	16	BASO_PC_BLD	Basophils, %, Blood
HEMATOLOGY	17	ANC_BLD	Absolute Neutrophil Count (A
HEMATOLOGY	18	BANDS_NUM_BLD	Neutrophil Bands, #, Blood
HEMATOLOGY	19	LYMPH_NUM_BLD	Lymphocytes, #, Blood
HEMATOLOGY	20	MONO_NUM_BLD	Monocytes, #, Blood
HEMATOLOGY	21	EOSINOPHIL_NUM_BLD	Eosinophils, #, Blood
HEMATOLOGY	22	BASO_NUM_BLD	Basophils, #, Blood
HEMATOLOGY	23	RETIC_PC_RBC	Reticulocytes, %, Red Blood
HEMATOLOGY	24	PMV_BLD	Platelet Mean Volume (PMV)
HLA TYPING (HLA)	1	HLA_A_AG_WBC	HLA A Antigen, White Blood
HLA TYPING (HLA)	2	HLA_A02_AG_WBC	HLA-A2 Antigen, White Bloo
HLA TYPING (HLA)	3	HLA_B_AG_WBC	HLA B Antigen, White Blood
HLA TYPING (HLA)	4	HLA_CW_AG_WBC	HLA Cw Antigen, White Blo
HLA TYPING (HLA)	5	HLA_DRB1_AG_WBC	HLA DRB1 Antigen, White I
HLA TYPING (HLA)	6	HLA_DRB_AG_WBC	HLA DRB Antigen, White Bl
HLA TYPING (HLA)	7	ABO_RH_BLD	ABO Group, Rh Type, Blood
HLA TYPING (HLA)	8	AB_SCREEN_SER	Antibody Screen, Serum
HLA TYPING (HLA)	9	HLA_DQB1_AG_WBC	HLA DQB1 Antigen, White I
HLA TYPING (HLA)	10	DAT_RBC	Direct Antiglobulin Test (Coo
LYMPHOCYTE PHENOTYPE TBNK	1	CD2_CELLS_NUM_BLD	CD2 Cells, #, Blood
LYMPHOCYTE PHENOTYPE TBNK	2	CD2_CELLS_PC_BLD	CD2 Cells, %, Blood
LYMPHOCYTE PHENOTYPE TBNK	2	CD2_CELLS_PC_BLD	CD2 Cells, %, Blood
LYMPHOCYTE PHENOTYPE TBNK	3	CD3_NUM_BLD	CD3 Cells, #, Blood
LYMPHOCYTE PHENOTYPE TBNK	4	CD3_PC_FC_BLD	CD3 Cells, %, Flow Cytomet
LYMPHOCYTE PHENOTYPE TBNK	5	CD3_CD4_CD8_NUM_BLD	CD3/CD4/CD8 Cells, #, Bloo

LYMPHOCYTE PHENOTYPE TBNK 8 CD3 CD8 CD25 NUM BLD CD3/8/25, %, Blood LYMPHOCYTE PHENOTYPE TBNK 9 CD3 CD8 CD25 PC BLD CD3/8/25, %, Blood LYMPHOCYTE PHENOTYPE TBNK 10 CD3/CD16 NUM_BLD CD3/CD16 Cd18, %, Blood LYMPHOCYTE PHENOTYPE TBNK 11 CD3/CD25 PC BLD CD3/CD16 Cd18, %, Blood LYMPHOCYTE PHENOTYPE TBNK 11 CD3/CD25 PC BLD CD3/CD25 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 12 CD3/CD25 PC BLD CD3/CD25 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 13 CD3/CD36 PC BLD CD3/CD36 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3/CD36 PC BLD CD3/CD56 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3/CD56 PC BLD CD3/CD56 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3/CD56 PC BLD CD3/CD56 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4 NUM BLD CD4 Cells, %, Flow Cytomet LYMPHOCYTE PHENOTYPE TBNK 16 CD4/CD3/CD6 PC BLD CD3/CD56 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 17 CD4/CD3/DCB NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 18 CD4/CD3/DCB NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 19 CD4/CD3/DCB NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 20 CD4/CD3/DCB NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 21 CD4/CD3/DCB NUM_BLD CD4/CD25/CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 21 CD4/CD3/DCB NUM_BLD CD4/CD25/CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 21 CD8/DCB NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 22 CD8/DCB NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 23 CD8/DCB NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 24 CD8/DCB NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8/CD3/DCB NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD9/CELLS_NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9/CELLS_NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD9/CELLS_NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9/CELLS_NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9/CELLS_NUM_BLD CD8/CB3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD9/CELLS_NUM_BLD CD8/CB1, #, Blood CD9/CB3, #, Blood CD9/CB3, #, Blood CD9/CB	LYMPHOCYTE PHENOTYPE TBNK	6	CD3_CD4_CD8_PC_BLD	CD3/CD4/CD8 Cells, %, Blo
LYMPHOCYTE PHENOTYPE TBNK 9 CD3 CD16 PC BLD CD3/CD16 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 10 CD3 CD16 PC BLD CD3/CD16 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 11 CD3 CD25 NUM BLD CD3/CD25 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 12 CD3 CD25 PC BLD CD3/CD25 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 13 CD3 CD25 PBLD CD3/CD25 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3 CD56 PC BLD CD3/CD26 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4 CD4 CD4 CD3/CD26 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4 NUM_BLD CD4 CD3/CD56 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4 NUM_BLD CD4 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 16 CD4 PC PC_BLD CD3/CD56 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 17 CD4 CD3 NUM_BLD CD4 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 18 CD4_CD3 NUM_BLD CD4 Cells to CD3 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 19 CD4_CD3 NUM_BLD CD4 Cells to CD3 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 19 CD4_CD3 NUM_BLD CD4 Cells to CD3 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 19 CD4_CD2_SCD3. NUM_BLD CD4 Cclls to CD3 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 20 CD4_CD2_SCD3. NUM_BLD CD4-CD2_SCD3 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 21 CD4_CD2_SCD3. NUM_BLD CD4-CD2_SCD3 Cclls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 22 CD8_NUM_BLD CD8-CClls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 23 CD8_PC_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 24 CD8_CD3_NUM_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_PC_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD8_CD3_PC_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD8_CD3_PC_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9_CCLLS_NUM_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD8_CCLLS_NUM_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9_CCLLS_NUM_BLD CD8-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9_CCLLS_NUM_BLD CD2-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9_CCLLS_NUM_BLD CD2-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9_CCLLS_NUM_BLD CD2-CGlls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD9_CCLLS_N		-		
LYMPHOCYTE PHENOTYPE TBNK 0		1		
LYMPHOCYTE PHENOTYPE TBNK 10 CD3.CD16 PC_BLD CD3:CD16 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 11 CD3.CD25 PC_BLD CD3:CD25 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 12 CD3.CD25 PC_BLD CD3:CD25 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3.CD56 PC_BLD CD3:CD56 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3.CD56 PC_BLD CD3:CD56 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4.NUM_BLD CD4:Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 16 CD4.PC_PC_BLD CD4:Cdls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 17 CD4.CD3_NUM_BLD CD4 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 18 CD4.CD3_PC_BLD CD4 Cclls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 19 CD4.CD3_NUM_BLD CD4 Cclls to CD3 Cclls, %, B LYMPHOCYTE PHENOTYPE TBNK 19 CD4.CD3_PC_BLD CD4 Cclls to CD3 Cclls, %, B LYMPHOCYTE PHENOTYPE TBNK 19 CD4.CD3_PC_BLD CD4 Cclls to CD3 Cclls, %, B LYMPHOCYTE PHENOTYPE TBNK 10 CD4.CD25.CD3.NUM_BLD CD4:CD25:CD3.Cclls, %, B LYMPHOCYTE PHENOTYPE TBNK 10 CD4.CD25.CD3.PC_BLD CD4:CD25:CD3.RD, &, B LYMPHOCYTE PHENOTYPE TBNK 10 CD8.CD3.RUM_BLD CD8.CClls, %, B Bood LYMPHOCYTE PHENOTYPE TBNK 10 CD8.CD3.RUM_BLD CD8.CD3.RUM_BLD CD8.CD3.RUM_BLD CD8.CD3.RUM_BLD CD8.CD3.RUM_BLD CD8.CD3.RUM_BLD CD9.CBL.RUM_BLD CD9		_		
LYMPHOCYTE PHENOTYPE TBNK 1		1		
LYMPHOCYTE PHENOTYPE TBNK 13 CD3_CD56_NUM_BLD CD3/CD56_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 14 CD3_CD56_NUM_BLD CD3/CD56_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4_NUM_BLD CD4_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 16 CD4_NUM_BLD CD4_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 16 CD4_PC_FC_BLD CD4_Cells, %, Flow Cytomet LYMPHOCYTE PHENOTYPE TBNK 17 CD4_CD3_NUM_BLD CD4_Cells, %, Flow Cytomet LYMPHOCYTE PHENOTYPE TBNK 18 CD4_CD3_PUM_BLD CD4_Cells to CD3_Cells, %, I LYMPHOCYTE PHENOTYPE TBNK 19 CD4_CD3_PUM_BLD CD4_Cells to CD3_Cells, %, I LYMPHOCYTE PHENOTYPE TBNK 19 CD4_CD3_PUM_BLD CD4_Cells to CD3_Cells, %, I LYMPHOCYTE PHENOTYPE TBNK 20 CD4_CD2_CD3_NUM_BLD CD4_CD2_S/CD3_Cells, %, BI LYMPHOCYTE PHENOTYPE TBNK 21 CD4_CD2_CD3_NUM_BLD CD4_CD2_S/CD3_Cells, %, BI LYMPHOCYTE PHENOTYPE TBNK 22 CD8_NUM_BLD CD8_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 23 CD8_PC_FC_BLD CD8_CD3_NUM_BLD CD8_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 24 CD8_CD3_NUM_BLD CD8_CElls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_PC_BLD CD8/CD3, %, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_PUM_BLD CD9_Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_PC_BLD CD8/CD3, %, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD8/CD3, %, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD2_CELLS_PC_BLD CD2_CR_B, %, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD2_CELLS_PC_BLD CD2_CR_B, %, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD2_CELLS_PC_BLD CD2_CR_B, %, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_PC_BLD Natural Killer (NK) Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_PC_BLD Natural Killer (NK) Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_PC_BLD Natural Killer (NK) Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_PC_BLD Natural Killer (NK) Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_PC_BLD Natural				
LYMPHOCYTE PHENOTYPE TBNK 14 LYMPHOCYTE PHENOTYPE TBNK 14 LYMPHOCYTE PHENOTYPE TBNK 15 CD4_NUM_BLD CD3/CD56 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 15 CD4_NUM_BLD CD4 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 16 CD4_PC_FC_BLD CD4 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 17 CD4_CD3_NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 18 LYMPHOCYTE PHENOTYPE TBNK 18 LYMPHOCYTE PHENOTYPE TBNK 19 CD4_CD3_NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 20 CD4_CD25_CD3_NUM_BLD CD4 Cells to CD3 Cells, #, B LYMPHOCYTE PHENOTYPE TBNK 21 LYMPHOCYTE PHENOTYPE TBNK 21 LYMPHOCYTE PHENOTYPE TBNK 22 CD8_NUM_BLD CD4_CD25_CD3_PC_BLD CD8 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 23 CD8_PC_BLD CD8_CD3_NUM_BLD CD8_CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 24 CD8_CD3_NUM_BLD CD8_CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_PC_BLD CD8_CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD9_CBLLS_NUM_BLD CD9_CELLS_NUM_BLD CD9_CELLS_NUM_BLD LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19_CELLS_PC_BLD LYMPHOCYTE PHENOTYPE TBNK 28 CD2_CELLS_NUM_BLD CD19_CELLS_PC_BLD CD19_CELLS_PC_BLD CD19_CELLS_PC_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NK) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NK) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NK) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NK) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NG) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NG) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NG) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD Natural Killer (NG) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Ki		_		
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE PHENOTY	LYMPHOCYTE PHENOTYPE TBNK	13		
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE LYMPHOCYT	LYMPHOCYTE PHENOTYPE TBNK	14	CD3_CD56_PC_BLD	CD3/CD56 Cells, %, Blood
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE LYMPHOCYT	LYMPHOCYTE PHENOTYPE TBNK	15	CD4_NUM_BLD	CD4 Cells, #, Blood
LYMPHOCYTE PHENOTYPE TBNK 18	LYMPHOCYTE PHENOTYPE TBNK	16	CD4_PC_FC_BLD	CD4 Cells, %, Flow Cytomet
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE PHENOTYPE TBNK CD4_CD25_CD3_NUM_BLD CD4/CD25/CD3 Cells, #, Blo CD25/CELLS_CD4 Cells	LYMPHOCYTE PHENOTYPE TBNK	17	CD4_CD3_NUM_BLD	CD4 Cells to CD3 Cells, #, B
LYMPHOCYTE PHENOTYPE TBNK 21 CD4_CD25_CD3_NUM_BLD CD4/CD25/CD3 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 22 CD8_NUM_BLD CD8 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 23 CD8_PC_FC_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 24 CD8_CD3_NUM_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_NUM_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_NUM_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_PC_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD20_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD20_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_PC_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25_CELS, #, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCBLL_NUM_BLD Natural Killer TCells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCBLL_NUM_BLD Natural Killer TCells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCBLL_NUM_BLD Natural Killer TCells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCBLL_NUM_BLD Natural Killer TCells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCBLL_NUM_BLD Natural Killer TCells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCBLL_NUM_BLD NATURAL KILLER TCELLS, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCBLL_NUM_BLD NATURAL KILLER TCELLS, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCBLL_NUM_BLD NATURAL KILLER TCELLS, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCBLL_NUM_BLD NATURAL KILLER TCELLS, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCBLL_NUM_BLD NATURAL KILLER TCELLS, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCBLL_NUM_BLD NATURAL KILLER TCELLS, #, Blood	LYMPHOCYTE PHENOTYPE TBNK	18	CD4_CD3_PC_BLD	CD4 Cells to CD3 Cells, %, I
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE LEDIA LYMPHOLY LYMPHOLY LYMPHOCYTE LEDIA LYMPHOLY LYMPHOLY LYMPHOCYTE LEDIA LYMPHOLY LY	LYMPHOCYTE PHENOTYPE TBNK	19	CD4_CD8_RTO_BLD	CD4 Cells to CD8 Cells Ratio
LYMPHOCYTE PHENOTYPE TBNK 22 CD8_NUM_BLD CD8 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 23 CD8_PC_FC_BLD CD8 Cells, #, Flow Cytomet LYMPHOCYTE PHENOTYPE TBNK 24 CD8_CD3_NUM_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_PC_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_NUM_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD20_CELLS_PC_BLD CD20_#, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD20_CELLS_PC_BLD CD20_#, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_NUM_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD20_#, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD20_#, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CNS_CELLS_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 32 NK_PC_BLD Natural Killer (NK) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 39 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood Natural Kille	LYMPHOCYTE PHENOTYPE TBNK	20	CD4_CD25_CD3_NUM_BLD	CD4/CD25/CD3 Cells, #, Blo
LYMPHOCYTE PHENOTYPE TBNK 24 CD8_CD3_NUM_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_PC_BLD CD8/CD3, #, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_NUM_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD20_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD20_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_NUM_BLD CD25_CBLS_#, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25_CBLS_#, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25_CBLS_#, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer (NK) Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #0, Blood NATURAL KILLER T CELLS_NUM_BLD NATURA	LYMPHOCYTE PHENOTYPE TBNK	21	CD4_CD25_CD3_PC_BLD	CD4/CD25/CD3 Cells, %, Bl
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE PHENOTY	LYMPHOCYTE PHENOTYPE TBNK	22	CD8_NUM_BLD	
LYMPHOCYTE PHENOTYPE TBNK 25 CD8_CD3_PC_BLD CD8/CD3, %, Blood LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_NUM_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD20_CELLS_PC_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD20_CELLS_PC_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_PC_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_NUM_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD CD25_CElls, %, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer (Tolls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cel		+		CD8 Cells, %, Flow Cytomet
LYMPHOCYTE PHENOTYPE TBNK 26 CD19_CELLS_NUM_BLD CD19 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD19 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD20_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD20_CELLS_PC_BLD CD20, %, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_PC_BLD CD25_CELLS_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer T Cells, #, Blood NATURAL KILLER CONTINUE TO CONTINUE TO CALCIUM_BLD NATURAL KILLER CONTINUE TO CALCIUM_BLD NATURAL KILLER CONTINUE TO CALCIUM_BLD NATURAL KILLER CONTINUE TO CALCIUM_IONIZED_SER C	LYMPHOCYTE PHENOTYPE TBNK	_	CD8_CD3_NUM_BLD	CD8/CD3, #, Blood
LYMPHOCYTE PHENOTYPE TBNK 27 CD19_CELLS_PC_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 28 CD20_CELLS_NUM_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 29 CD20_CELLS_PC_BLD CD20, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_PC_BLD CD25 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 36 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 37 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_SPC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 38 NK_TCELL_SPC_BLD Natural Killer T Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 3		_		
LYMPHOCYTE PHENOTYPE TBNK LYMPHOCYTE PHENOTY				
LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_PC_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_NUM_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25_CElls, #, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo CTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Cl OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER				
LYMPHOCYTE PHENOTYPE TBNK 30 CD25_CELLS_NUM_BLD CD25 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25 Cells, #, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo OTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Cl OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER		+		
LYMPHOCYTE PHENOTYPE TBNK 31 CD25_CELLS_PC_BLD CD25 Cells, %, Blood LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo OTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Ch OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 15 T3_SER Thyroxine (T4), Serum				
LYMPHOCYTE PHENOTYPE TBNK 32 NK_NUM_BLD Natural Killer (NK) Cells, #, LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, %, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo OTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Ch OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, Ch OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		+		
LYMPHOCYTE PHENOTYPE TBNK 33 NK_PC_BLD Natural Killer (NK) Cells, %, LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo OTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Chemistries 4 Insulin_Ser Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, Continuation, Chemistries 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Serum OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 16 T4_SER				
LYMPHOCYTE PHENOTYPE TBNK 34 NK_TCELL_NUM_BLD Natural Killer T Cells, #, Blo LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, #, Blo OTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Chemistries 4 Insulin_ser Insulin_serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, COTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 15 T3_SER Trijoproteine (T4), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum				
LYMPHOCYTE PHENOTYPE TBNK 35 NK_TCELL_PC_BLD Natural Killer T Cells, %, Blocother Serum Chemistries 1 Calcium_Ionized_Ser Calcium, Ionized, Serum Other Serum Chemistries 2 Ferritin_Ser Ferritin, Serum Other Serum Chemistries 3 HDLC_Ser High Density Lipoprotein, Chemistries 4 Insulin_Ser Insulin, Serum Other Serum Chemistries 5 Iron_Ser Iron, Serum Other Serum Chemistries 6 Iron_Satn_ro_Ser Iron Saturation, Ratio, Serum Other Serum Chemistries 7 LDLC_Ser Low Density Lipoproteins, Cother Serum Chemistries 8 Lipase_Ser Lipase, Serum Other Serum Chemistries 9 Amylase_Ser Lipase, Serum Other Serum Chemistries 10 Haptoglob_Ser Haptoglobin, Serum Other Serum Chemistries 11 Osmolality_Serum Other Serum Chemistries 12 ACP_Ser Acid Phosphatase (ACP), Ser Other Serum Chemistries 13 Transferrin_Serum Transferrin, Serum Other Serum Chemistries 14 Trigly_Ser Triglycerides, Serum Other Serum Chemistries 14 Trigly_Ser Triiodothyronine (T3), Serum Other Serum Chemistries 15 T3_Ser Triiodothyronine (T3), Serum Other Serum Chemistries 15 T4_Ser Thyroxine (T4), Serum Other Serum Chemistries 16 T4_Ser Thyroxine (T4), Serum				1 1
OTHER SERUM CHEMISTRIES 1 CALCIUM_IONIZED_SER Calcium, Ionized, Serum OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Cr OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER CIPASE_SER OTHER SERUM CHEMISTRIES 9 AMYLASE_SER OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER OTHER SERUM CHEMISTRIES 12 ACP_SER OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		_		
OTHER SERUM CHEMISTRIES 2 FERRITIN_SER Ferritin, Serum OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Chemistry Chemistries OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, Chemistry Chemistries 8 LIPASE_SER OTHER SERUM CHEMISTRIES 9 AMYLASE_SER OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER OTHER SERUM CHEMISTRIES 12 ACP_SER OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		_		
OTHER SERUM CHEMISTRIES 3 HDLC_SER High Density Lipoprotein, Chemistries of the composition of the composit				
OTHER SERUM CHEMISTRIES 4 INSULIN_SER Insulin, Serum OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum			_	
OTHER SERUM CHEMISTRIES 5 IRON_SER Iron, Serum OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		+		<u> </u>
OTHER SERUM CHEMISTRIES 6 IRON_SATN_RTO_SER Iron Saturation, Ratio, Serum OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		_	_	· · · · · · · · · · · · · · · · · · ·
OTHER SERUM CHEMISTRIES 7 LDLC_SER Low Density Lipoproteins, C OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER OSMOLALITY_SER OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		_	_	
OTHER SERUM CHEMISTRIES 8 LIPASE_SER Lipase, Serum OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum		+		
OTHER SERUM CHEMISTRIES 9 AMYLASE_SER Amylase, Serum OTHER SERUM CHEMISTRIES 10 HAPTOGLOB_SER Haptoglobin, Serum OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	8		· · · · ·
OTHER SERUM CHEMISTRIES 11 OSMOLALITY_SER Osmolality, Serum OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	9	AMYLASE_SER	-
OTHER SERUM CHEMISTRIES 12 ACP_SER Acid Phosphatase (ACP), Ser OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	10	HAPTOGLOB_SER	Haptoglobin, Serum
OTHER SERUM CHEMISTRIES 13 TRANSFERRIN_SER Transferrin, Serum OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	11	OSMOLALITY_SER	Osmolality, Serum
OTHER SERUM CHEMISTRIES 14 TRIGLY_SER Triglycerides, Serum OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	12	ACP_SER	Acid Phosphatase (ACP), Ser
OTHER SERUM CHEMISTRIES 15 T3_SER Triiodothyronine (T3), Serum OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	13	TRANSFERRIN_SER	Transferrin, Serum
OTHER SERUM CHEMISTRIES 16 T4_SER Thyroxine (T4), Serum	OTHER SERUM CHEMISTRIES	14	TRIGLY_SER	Triglycerides, Serum
	OTHER SERUM CHEMISTRIES	15	T3_SER	Triiodothyronine (T3), Serum
OTHER SERUM CHEMISTRIES 17 TSH_SER Thyrotropin (Thyroid Stimula	OTHER SERUM CHEMISTRIES	16	T4_SER	Thyroxine (T4), Serum
	OTHER SERUM CHEMISTRIES	17	TSH_SER	Thyrotropin (Thyroid Stimula

OTHER SERUM CHEMISTRIES	18	CHOLEST_SER	Cholesterol, Serum
OTHER SERUM CHEMISTRIES	19	CHOLESTANOL_SER	Cholestanol, Serum
OTHER SERUM CHEMISTRIES	20	BETA2_MICRGLOB_SER	Beta-2 Microglobulin, Serum
OTHER SERUM CHEMISTRIES	21	HGB_A1C_BLD	Hemoglobin (Hgb) A1C, Block
OTHER SERUM CHEMISTRIES	22	GGT_SER	Gamma Glutamyl Transferase
OTHER URINARY RESULTS	1	CALCIUM_24H_UR	Calcium, 24 hour, Urine
OTHER URINARY RESULTS	2	CHLORIDE_24H_UR	Chloride, 24 hour, Urine
OTHER URINARY RESULTS	3	OSMOLALITY_24H_UR	Osmolality, 24 hour, Urine
OTHER URINARY RESULTS	4	POTASSIUM_24H_UR	Potassium, 24 hour, Urine
OTHER URINARY RESULTS	5	SODIUM_24H_UR	Sodium, 24 hour, Urine
OTHER URINARY RESULTS	6	URATE_24H_UR	Uric Acid (Urate), 24 hour, U
OTHER URINARY RESULTS	7	CREATININE_CL24H_UR	Creatinine Clearance, 24 hour
OTHER URINARY RESULTS	8	CREATININE_UR	Creatinine, Spot or Timed Sar
OTHER URINARY RESULTS	9	PROTEIN_24H_UR	Protein, 24 hour, Urine Note name (For example: the prote
OTTUEN LINEAU STATES	10	DD OTTENA TAKE A 122 A 122	D
OTHER URINARY RESULTS	10	PROTEIN_EXC_24H_UR	Protein excretion, 24 hour, U
OTHER URINARY RESULTS	11	BHCG_PREG_UR	Beta Choriogonadotropin (BF
OTHER URINARY RESULTS	12	VOLUME_UR	Volume, Urine
PULMONARY FUNCTION TESTS	1	VC_RESYS	Vital Capacity (VC), Respirat
PULMONARY FUNCTION TESTS	2	EXP_VOL_RESYS	Expiratory Volume, Respirator
PULMONARY FUNCTION TESTS	3	MAX_C_RESYS	Forced Vital Capacity (Maxin
PULMONARY FUNCTION TESTS	4	VOL_RES_RESYS	Volume Residual, Respiratory
PULMONARY FUNCTION TESTS	5	FUNCT_RES_C_RESYS	Functional Residual Capacity
PULMONARY FUNCTION TESTS	6	DIFFUS_CAP_RESYS	Diffusion Capacity, Respirato
PULMONARY FUNCTION TESTS	7	DIFF_CAP_PRED_RESYS	Diffusing Capacity % Predict
PULMONARY FUNCTION TESTS	8	MAX_FXP_FLOW_RESYS	Maximum Forced Expiratory
PULMONARY FUNCTION TESTS	9	FEV1_RESYS	Forced Expiratory Volume, R
PULMONARY FUNCTION TESTS	10	FEV1_PRED_RESYS	Forced Expiratory Volume %
PULMONARY FUNCTION TESTS	11	FVC_RESYS	Forced Vital Capacity (FVC),
PULMONARY FUNCTION TESTS	12	FVC_PRED_RESYS	Forced Vital Capacity (FVC)
PULMONARY FUNCTION TESTS	13	DL_VA_RTO_RESYS	Diffusing Capacity to Alveola
PULMONARY FUNCTION TESTS	14	DL_VA_RTO_PRED_RESYS	Diffusing Capacity to Alveola
PULMONARY FUNCTION TESTS	15	FEF25_75_RESYS	Volume expelled during midp
PULMONARY FUNCTION TESTS	16	FEF25_75_PRED_RESYS	Volume expelled during midp
PULMONARY FUNCTION TESTS	17	CAP TTL RESYS	Total Lung Capacity %, Resp
PULMONARY FUNCTION TESTS	18	CAP_TTL_PRED_RESYS	Total Lung Capacity %, Predi
PULMONARY FUNCTION TESTS	19	FEV1_FVC_RTO_RESYS	FEV1 to FVC Ratio, Respirat
PULMONARY FUNCTION TESTS	20	RV_TLC_RTO_RESYS	Residual Volume to Total Lui
SEROLOGY	1	PSA_SER	Prostate Specific Antigen (PS
SEROLOGY	2	CA125_SER	Carcinogenic Antigen 125 (C
SEROLOGY	3	CEA_SER	Carcinoembryonic Antigen (C
SEROLOGY	4	CA19_9_SER	Carcinogenic Antigen 19-9 (C
SEROLOGY	5	CA15_3_SER	Carcinogenic Antigen 15-3 (C
SEROLOGY	6	CA13_3_SER CA27_29_SER	Cancer Antigen 27-29 (CA27
SEROLOGY	7	CA27_29_SER COMP_C3_SER	Complement, C3, Serum
DLKOLOG I	/	COMI _CJ_SEK	Complement, Co, Setuni
-		-	-

SEROLOGY	8	COMP_C4_SER	Complement, C4, Serum
SEROLOGY	9	HCG_SER	Human Choriogonadotropin (
SEROLOGY	10	HIV_1_2_AB_SER	Human Immunodeficiency Vi
SEROLOGY	11	CH50_SER	CH50 Complement, Serum
SEROLOGY	12	HBSAG_SER	Hepatitis B Surface Antigen,
SEROLOGY	13	HBSAG_AB_SER	Antibody to Hepatitis B surfa
SEROLOGY	14	HEP_C_AB_SER	Hepatitis C Antibody, Serum
SEROLOGY	15	BHCG_PREG_SER	Beta Choriogonadotropin BH
SERUM ELECTRO	1	ALBUMIN_ELPH_SER	Albumin, Electrophoresis, Se
SERUM ELECTRO	2	ALPHA1_GLOB_ELPH_SER	Alpha 1 Globulin, Protein Ele
SERUM ELECTRO	3	ALPHA2_GLOB_ELPH_SER	Alpha 2 Globulin, Protein Ele
SERUM ELECTRO	4	BETA_GLOB_ELPH_SER	Beta Globulin, Protein Electro
SERUM ELECTRO	5	GAMMA_GLOB_ELPH_SER	Gamma Globulin, Protein Ele
SERUM ELECTRO	6	PROTEIN_TTL_ELPH_SER	Total Protein Electrophoresis,
SERUM ELECTRO	7	IGA_SER	Immunoglobulin A (IgA), Ser
SERUM ELECTRO	8	IGD_SER	Immunoglobulin D (IgD), Set
SERUM ELECTRO	9	IGE_SER	Immunoglobulin E (IgE), Ser
SERUM ELECTRO	10	IGG_SER	Immunoglobulin G (IgG), Set
SERUM ELECTRO	11	IGM_SER	Immunoglobulin M (IgM), Se
URINALYSIS	1	GLUCOSE_UR	Glucose, Spot Urine
URINALYSIS	2	PROTEIN_QUAL_UR	Protein, Qualitative, Urine
URINALYSIS	3	UROBILINOGEN_UR	Urobilinogen, Spot Urine
URINALYSIS	4	PH_UR	pH, Spot Urine
URINALYSIS	5	HGB_UR	Hemoglobin, Spot Urine
URINALYSIS	6	KETONES_UR	Ketones, Spot Urine
URINALYSIS	7	NITRITE_UR	Nitrite, Spot Urine
URINALYSIS	8	LEUK_EST_UR	Leukocyte Esterase, Spot Urii
URINALYSIS	9	APPEAR_UR	Appearance, Urine
URINALYSIS	10	SPEC_GRAV_UR	Specific Gravity, Spot Urine
URINALYSIS	11	COLOR_UR	Color, Urine
URINALYSIS	12	RBC_MICRO_NUM_UR	Red Blood Cells (RBC), Micr
URINALYSIS	13	WBC_MICRO_NUM_UR	White Blood Cells (WBC), M
URINE IMMUNE ELECTRO	1	ALBUMIN_ELPH_TUR	Albumin, Electrophoresis, Tii
URINE IMMUNE ELECTRO	2	ALPHA1_GLOB_ELPH_TUR	Alpha 1 Globulin, Electropho
URINE IMMUNE ELECTRO	3	ALPHA2_GLOB_ELPH_TUR	Alpha 2 Globulin, Electropho
URINE IMMUNE ELECTRO	4	BETA_GLOB_ELPH_TUR	Beta Globulin, Electrophoresi
URINE IMMUNE ELECTRO	5	GAMMA_GLOB_ELPH_TUR	Gamma Globulin, Electropho

Appendix IV – Lab Load Interface (LLI) Tool

Under Construction.